

Supplemental Table 1: Citations of articles included in chronological order (n=231).

1. Radnai B, Takacs-Nagy L. [Neurolymphomatosis in man]. *Orv Hetil* 1951;92(48):1559-62
2. Borit A, Altrocchi PH. Recurrent polyneuropathy and neurolymphomatosis. *Arch Neurol* 1971;24(1):40-9 doi: 10.1001/archneur.1971.00480310068006[published Online First: Epub Date]].
3. Trelles JO, Urquiaga C, Palomino L, Trelles L. [Human peripheral neurolymphomatosis (reticuloendothelial polyradiculoneuritis)]. *J Neurol Sci* 1976;28(2):187-202 doi: 10.1016/0022-510x(76)90102-7[published Online First: Epub Date]].
4. Guberman A, Rosenbaum H, Braciale T, Schlaepfer WW. Human neurolymphomatosis. *J Neurol Sci* 1978;36(1):1-12 doi: 10.1016/0022-510x(78)90157-0[published Online First: Epub Date]].
5. Trelles JO, Trelles L. [Human peripheral neurolymphomatosis]. *Rev Neurol (Paris)* 1983;139(12):703-14
6. Guberman A. Fatal peripheral neurolymphomatosis. *Neurology* 1984;34(2):259-60 doi: 10.1212/wnl.34.2.259-a[published Online First: Epub Date]].
7. Woimant F, Schanen A, Bertail MA, et al. [Myelopathy manifesting as macroglobulinemia]. *Ann Med Interne (Paris)* 1985;136(2):121-4
8. Kuroda Y, Nakata H, Kakigi R, Oda K, Shibasaki H, Nakashiro H. Human neurolymphomatosis by adult T-cell leukemia. *Neurology* 1989;39(1):144-6 doi: 10.1212/wnl.39.1.144[published Online First: Epub Date]].
9. Grisold W, Jellinger K, Lutz D. Human neurolymphomatosis in a patient with chronic lymphatic leukemia. *Clin Neuropathol* 1990;9(5):224-30
10. Diaz-Arrastia R, Younger DS, Hair L, et al. Neurolymphomatosis: a clinicopathologic syndrome re-emerges. *Neurology* 1992;42(6):1136-41 doi: 10.1212/wnl.42.6.1136[published Online First: Epub Date]].
11. van den Bent MJ, de Bruin HG, Beun GD, Vecht CJ. Neurolymphomatosis of the median nerve. *Neurology* 1995;45(7):1403-5 doi: 10.1212/wnl.45.7.1403[published Online First: Epub Date]].
12. Swarnkar A, Fukui MB, Fink DJ, Rao GR. MR imaging of brachial plexopathy in neurolymphomatosis. *AJR Am J Roentgenol* 1997;169(4):1189-90 doi: 10.2214/ajr.169.4.9308489[published Online First: Epub Date]].
13. Abad S, Zagdanski AM, Brechignac S, Thioliere B, Brouet JC, Mariette X. Neurolymphomatosis in Waldenstrom's macroglobulinaemia. *Br J Haematol* 1999;106(1):100-3 doi: 10.1046/j.1365-2141.1999.01482.x[published Online First: Epub Date]].
14. Bower SP, McKelvie P, Peppard RW, Roberts L. Neurolymphomatosis presenting as mononeuritis multiplex. *J Clin Neurosci* 1999;6(6):530-2 doi: 10.1016/s0967-5868(99)90020-6[published Online First: Epub Date]].
15. van den Bent MJ, de Bruin HG, Bos GM, Brutel de la Riviere G, Sillevs Smitt PA. Negative sural nerve biopsy in neurolymphomatosis. *J Neurol* 1999;246(12):1159-63 doi: 10.1007/s004150050535[published Online First: Epub Date]].
16. Carey MJ, Smith AG, Townsend JJ. Pathologic quiz case: progressive diffuse weakness after chemotherapy for large cell lymphoma in a middle-aged woman. Lymphomatous meningitis with neurolymphomatosis. *Arch Pathol Lab Med* 2000;124(4):645-6 doi: 10.5858/2000-124-0645-PQC[published Online First: Epub Date]].

17. Kuntzer T, Lobrinus JA, Janzer RC, Ghika J, Bogouslavsky J. Clinicopathological and molecular biological studies in a patient with neurolymphomatosis. *Muscle Nerve* 2000;23(10):1604-9 doi: 10.1002/1097-4598(200010)23:10<1604::aid-mus21>3.0.co;2-f[published Online First: Epub Date]].
18. Pietrangeli A, Milella M, De Marco S, et al. Brachial plexus neuropathy as unusual onset of diffuse neurolymphomatosis. *Neurol Sci* 2000;21(4):241-5 doi: 10.1007/s100720070083[published Online First: Epub Date]].
19. Quinones-Hinojosa A, Friedlander RM, Boyer PJ, Batchelor TT, Chiocca EA. Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. *J Neurosurg* 2000;92(1):165-9 doi: 10.3171/jns.2000.92.1.0165[published Online First: Epub Date]].
20. Moore KR, Blumenthal DT, Smith AG, Ward JH. Neurolymphomatosis of the lumbar plexus: high-resolution MR neurography findings. *Neurology* 2001;57(4):740-2 doi: 10.1212/wnl.57.4.740[published Online First: Epub Date]].
21. Odabasi Z, Parrott JH, Reddy VV, Oh SJ. Neurolymphomatosis associated with muscle and cerebral involvement caused by natural killer cell lymphoma: a case report and review of literature. *J Peripher Nerv Syst* 2001;6(4):197-203 doi: 10.1046/j.1529-8027.2001.01018.x[published Online First: Epub Date]].
22. Trojan A, Jermann M, Taverna C, Hany TF. Fusion PET-CT imaging of neurolymphomatosis. *Ann Oncol* 2002;13(5):802-5 doi: 10.1093/annonc/mdf057[published Online First: Epub Date]].
23. Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. *Neuro Oncol* 2003;5(2):104-15 doi: 10.1093/neuonc/nop021[published Online First: Epub Date]].
24. Dakwar E, Teja S, Alleyne CH, Jr. Sciatic neurolymphomatosis. *Neurology* 2004;63(9):1751 doi: 10.1212/01.wnl.0000138501.06028.68[published Online First: Epub Date]].
25. Ghobrial IM, Buadi F, Spinner RJ, et al. High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. *Cancer* 2004;100(11):2403-7 doi: 10.1002/cncr.20263[published Online First: Epub Date]].
26. Pages M, Marty-Double C, Pages AM. Sensory neuropathy as revealing symptom of neurolymphomatosis: report of a case with a 15-year duration. *Eur Neurol* 2004;52(1):57-8 doi: 10.1159/000079545[published Online First: Epub Date]].
27. Bi HY, Na J, Zang GM, Zhang W, Yuan Y. [Neurolymphomatosis, a case report]. *Beijing Da Xue Xue Bao Yi Xue Ban* 2005;37(3):331
28. Bokstein F, Goor O, Shihman B, et al. Assessment of neurolymphomatosis by brachial plexus biopsy and PET/CT. Report of a case. *J Neurooncol* 2005;72(2):163-7 doi: 10.1007/s11060-004-3389-0[published Online First: Epub Date]].
29. Kanter P, Zeidman A, Streifler J, et al. PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. *Eur J Haematol* 2005;74(1):66-9 doi: 10.1111/j.1600-0609.2004.00369.x[published Online First: Epub Date]].
30. Kim JH, Jang JH, Koh SB. A case of neurolymphomatosis involving cranial nerves: MRI and fusion PET-CT findings. *J Neurooncol* 2006;80(2):209-10 doi: 10.1007/s11060-006-9164-7[published Online First: Epub Date]].
31. Ozturk E, Arpaci F, Kocaoglu M, Arslan N, Bulakbasi N, Ozguven M. Detection of widespread neurolymphomatosis with 18F-FDG PET. *Eur J Nucl Med Mol Imaging* 2006;33(8):975-6 doi: 10.1007/s00259-006-0146-y[published Online First: Epub Date]].

32. Rosso SM, de Bruin HG, Wu KL, van den Bent MJ. Diagnosis of neurolymphomatosis with FDG PET. *Neurology* 2006;67(4):722-3 doi: 10.1212/01.wnl.0000230155.67464.37[published Online First: Epub Date]].
33. Strobel K, Pestalozzi B, Ciernik I, Schaefer NG, Koma AY, Hany TF. Changing PET/CT manifestation of neurolymphomatosis. *Eur J Nucl Med Mol Imaging* 2006;33(10):1244 doi: 10.1007/s00259-006-0112-8[published Online First: Epub Date]].
34. Grisold W, Klimpfnger M, Maehr B, et al. Peripheral nerve involvement in lymphoma: the meninges as the crucial barrier between meningoradicular spread and neurolymphomatosis. *J Peripher Nerv Syst* 2007;12(1):58-60 doi: 10.1111/j.1529-8027.2007.00120.x[published Online First: Epub Date]].
35. Hoshikawa Y, Oguri T, Hattori M, et al. [A case of neurolymphomatosis diagnosed with FDG-PET]. *Rinsho Shinkeigaku* 2007;47(7):437-40
36. Rahmani M, Birouk N, Amarti A, et al. [T-cell lymphoma revealed by a mononeuritis multiplex: case report and review of literature]. *Rev Neurol (Paris)* 2007;163(4):462-70 doi: 10.1016/s0035-3787(07)90422-1[published Online First: Epub Date]].
37. Shibata-Hamaguchi A, Samuraki M, Furui E, et al. B-cell neurolymphomatosis confined to the peripheral nervous system. *J Neurol Sci* 2007;260(1-2):249-52 doi: 10.1016/j.jns.2007.03.029[published Online First: Epub Date]].
38. Strobel K, Fischer K, Hany TF, Poryazova R, Jung HH. Sciatic nerve neurolymphomatosis - extent and therapy response assessment with PET/CT. *Clin Nucl Med* 2007;32(8):646-8 doi: 10.1097/RLU.0b013e3180a1ac74[published Online First: Epub Date]].
39. Tachibana T, Tomita N, Ueda T, et al. [Systemic neurolymphomatosis complicated in diffuse large B-cell lymphoma]. *Rinsho Ketsueki* 2007;48(12):1563-6
40. Yazawa S, Ohi T, Shiomi K, Takashima N, Kyoraku I, Nakazato M. Brachial plexus neurolymphomatosis: a discrepancy between electrophysiological and radiological findings. *Intern Med* 2007;46(8):533-4 doi: 10.2169/internalmedicine.46.6153[published Online First: Epub Date]].
41. Chaturvedi A, Singh JP, Rastogi V. MRI diagnosis of neurolymphomatosis of the brachial plexus. *Neurol India* 2008;56(4):485-6 doi: 10.4103/0028-3886.44817[published Online First: Epub Date]].
42. Czepczynski R, Guzikowska-Ruszkowska I, Sowinski J. Neurolymphomatosis detected by (18)F-FDG PET/CT scan - a case report. *Nucl Med Rev Cent East Eur* 2008;11(2):73-5
43. Dong Q, Wong KK, Avram AM. Sacral nerve root neurolymphomatosis diagnosed on FDG-PET/CT and magnetic resonance imaging. *Clin Nucl Med* 2008;33(1):30-1 doi: 10.1097/RLU.0b013e31815c5020[published Online First: Epub Date]].
44. Khong P, Pitham T, Owler B. Isolated neurolymphomatosis of the cauda equina and filum terminale: case report. *Spine (Phila Pa 1976)* 2008;33(21):E807-11 doi: 10.1097/BRS.0b013e31818441be[published Online First: Epub Date]].
45. Levin N, Soffer D, Grissaru S, Aizikovitch N, Gomori JM, Siegal T. Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis. *J Neurooncol* 2008;90(1):77-83 doi: 10.1007/s11060-008-9633-2[published Online First: Epub Date]].
46. Lin M, Kilanowska J, Taper J, Chu J. Neurolymphomatosis--diagnosis and assessment of treatment response by FDG PET-CT. *Hematol Oncol* 2008;26(1):43-5 doi: 10.1002/hon.837[published Online First: Epub Date]].

47. Shima K, Ishida C, Okino S, Kotani T, Higashi K, Yamada M. A linear lesion along the brachial plexus on FDG-PET in neurolymphomatosis. *Intern Med* 2008;47(12):1159-60 doi: 10.2169/internalmedicine.47.1104[published Online First: Epub Date]].
48. Urban PP, Kaczmarek E, Wellach I, et al. [Neurolymphomatosis. Subacute sensorimotor polyneuropathy as a first sign of non-Hodgkin's B cell lymphoma]. *Nervenarzt* 2008;79(6):699-702 doi: 10.1007/s00115-008-2456-8[published Online First: Epub Date]].
49. Bezier M, Reguiat Z, Delaby P, et al. Neurolymphomatosis associated with Sezary syndrome. *Arch Dermatol* 2009;145(3):294-6 doi: 10.1001/archdermatol.2008.584[published Online First: Epub Date]].
50. Chamberlain MC, Fink J. Neurolymphomatosis: a rare metastatic complication of diffuse large B-Cell lymphoma. *J Neurooncol* 2009;95(2):285-88 doi: 10.1007/s11060-009-9918-0[published Online First: Epub Date]].
51. Duran C, Infante JR, Serrano J, et al. [Neurolymphomatosis: diagnosis of extension and assessment of response to treatment with PET-CT]. *Rev Esp Med Nucl* 2009;28(6):295-8 doi: 10.1016/j.rem.2009.07.002[published Online First: Epub Date]].
52. Hong RS, Woodson EA, Hansen MR. Neurolymphomatosis mimicking chemotherapy-induced ototoxicity. *Otol Neurotol* 2009;30(4):566-9 doi: 10.1097/MAO.0b013e3181a527b2[published Online First: Epub Date]].
53. Kosa SC, Peller PJ, Klein CJ. T-cell neurolymphomatosis involving cauda equina and sciatic nerves. *Neurology* 2009;72(1):98 doi: 10.1212/01.wnl.0000338598.07063.5b[published Online First: Epub Date]].
54. Nishio M, Tamaki T, Ochi H, Shibamoto Y. Intraspinal canal neurolymphomatosis detected by FDG-PET/CT. *Clin Nucl Med* 2009;34(9):610-2 doi: 10.1097/RLU.0b013e3181b06c76[published Online First: Epub Date]].
55. Peruzzi P, Ray-Chaudhuri A, Slone WH, Mekhjian HS, Porcu P, Chiocca E. Reversal of neurological deficit after chemotherapy in BCL-6-positive neurolymphomatosis. Case report. *J Neurosurg* 2009;111(2):247-51 doi: 10.3171/2008.11.JNS08291[published Online First: Epub Date]].
56. von Falck C, Rodt T, Joerdens S, et al. F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound. *Clin Nucl Med* 2009;34(8):493-5 doi: 10.1097/RLU.0b013e3181abb6ba[published Online First: Epub Date]].
57. Gan HK, Azad A, Cher L, Mitchell PL. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. *Neuro Oncol* 2010;12(2):212-5 doi: 10.1093/neuonc/nop021[published Online First: Epub Date]].
58. Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. *Blood* 2010;115(24):5005-11 doi: 10.1182/blood-2009-12-258210[published Online First: Epub Date]].
59. Koyama T, O'Uchi T, Matsue K. Neurolymphomatosis involving the trigeminal nerve and deep peroneal nerve in a patient with relapsed intravascular large B-cell lymphoma. *Eur J Haematol* 2010;85(3):275-6 doi: 10.1111/j.1600-0609.2010.01477.x[published Online First: Epub Date]].
60. Miki M, Masaki Y, Nakamura T, et al. [Primary neurolymphomatosis of the cervical nerve root]. *Rinsho Ketsueki* 2010;51(7):564-7

61. Nishizawa M, Yamashita K, Nakamoto Y, Kotani S, Kondo T, Takaori-Kondo A. Neurolymphomatosis as a manifestation of relapsed primary cardiac lymphoma. *Int J Hematol* 2010;92(5):679-80 doi: 10.1007/s12185-010-0716-4[published Online First: Epub Date]].
62. Santos E, Scolding NJ. Neurolymphomatosis mimicking neurosarcoidosis: a case report. *J Med Case Rep* 2010;4:5 doi: 10.1186/1752-1947-4-5[published Online First: Epub Date]].
63. Ye BS, Sunwoo IN, Suh BC, Park JP, Shim DS, Kim SM. Diffuse large B-cell lymphoma presenting as piriformis syndrome. *Muscle Nerve* 2010;41(3):419-22 doi: 10.1002/mus.21538[published Online First: Epub Date]].
64. Cassereau J, Letournel F, Francois S, Dubas F, Nicolas G. Chronic inflammatory demyelinating polyneuropathy in Waldenstrom's macroglobulinemia. *Rev Neurol (Paris)* 2011;167(4):343-7 doi: 10.1016/j.neurol.2010.10.015[published Online First: Epub Date]].
65. Hong CM, Lee SW, Lee HJ, et al. Neurolymphomatosis on F-18 FDG PET/CT and MRI Findings: A Case Report. *Nucl Med Mol Imaging* 2011;45(1):76-8 doi: 10.1007/s13139-010-0070-8[published Online First: Epub Date]].
66. Hung MH, Gau JP. Relapsed testicular lymphoma presenting with cranial nerve neurolymphomatosis. *Neurology* 2011;76(16):1441 doi: 10.1212/WNL.0b013e318216711a[published Online First: Epub Date]].
67. Matsue K, Hayama BY, Iwama K, et al. High frequency of neurolymphomatosis as a relapse disease of intravascular large B-cell lymphoma. *Cancer* 2011;117(19):4512-21 doi: 10.1002/ncr.26090[published Online First: Epub Date]].
68. Suga K, Yasuhiko K, Matsunaga N, Yujiri T, Nakazora T, Ariyoshi K. F-18 FDG PET/CT findings of a case of sacral nerve root neurolymphomatosis that occurred during chemotherapy. *Clin Nucl Med* 2011;36(1):73-6 doi: 10.1097/RLU.0b013e3181f4a03f[published Online First: Epub Date]].
69. Talanow R, Shrikanthan S. Value of FDG PET in the evaluation of therapy response in nerve root neurolymphomatosis. *Clin Nucl Med* 2011;36(5):389-91 doi: 10.1097/RLU.0b013e31820a9fab[published Online First: Epub Date]].
70. Casselberry JN, Kritz AD. Neurolymphomatosis: a case study of diffuse large B-cell lymphoma. *Clin J Oncol Nurs* 2012;16(6):636-7 doi: 10.1188/12.CJON.636-637[published Online First: Epub Date]].
71. Cheung C, Lopes D, Hung KN, Chan T, Chan KW, Kwong YL. Neurolymphomatosis: role of positron emission tomography in diagnosis. *Ann Hematol* 2012;91(8):1313-4 doi: 10.1007/s00277-011-1379-9[published Online First: Epub Date]].
72. D'Amico A, Napoli M, Cirillo M, et al. Imaging of cervical extradural en-plaque meningioma. A case report. *Neuroradiol J* 2012;25(5):598-603 doi: 10.1177/197140091202500514[published Online First: Epub Date]].
73. Gs B, J G, S LAM, et al. Bilateral vagus nerve neurolymphomatosis diagnosed using PET/CT and diffusion-weighted MRI. *Clin Nucl Med* 2012;37(9):e225-8 doi: 10.1097/RLU.0b013e318251e474[published Online First: Epub Date]].
74. Harada N, Tomita M, Kimura A, et al. [Case report; Two cases of neurolymphomatosis as a manifestation of relapsed non-Hodgkin lymphoma]. *Nihon Naika Gakkai Zasshi* 2012;101(1):157-60 doi: 10.2169/naika.101.157[published Online First: Epub Date]].
75. Pentsova E, Rosenblum M, Holodny A, Palomba ML, Omuro A. Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular

- liposomal cytarabine and high dose methotrexate for neurolymphomatosis. *Leuk Lymphoma* 2012;53(8):1620-2 doi: 10.3109/10428194.2012.656632[published Online First: Epub Date]].
76. Sugai A, Konno T, Yano T, Umeda M, Oyake M, Fujita N. [Neurolymphomatosis presenting as bilateral tongue atrophy: a case report]. *Rinsho Shinkeigaku* 2012;52(8):589-91 doi: 10.5692/clinicalneuro.52.589[published Online First: Epub Date]].
 77. Tsang HH, Lee EY, Anthony MP, Khong PL. 18F-FDG PET/CT diagnosis of vagus nerve neurolymphomatosis. *Clin Nucl Med* 2012;37(9):897-8 doi: 10.1097/RLU.0b013e31825b2042[published Online First: Epub Date]].
 78. Vecchio D, Mittino D, Terazzi E, Nassi L, Conconi A, Monaco F. A case of cranial multinevritis: from the onset to the diagnosis of primary neurolymphomatosis. *BMJ Case Rep* 2012;2012 doi: 10.1136/bcr.06.2011.4299[published Online First: Epub Date]].
 79. Wan MY, Ardeshtna KM, Bomanji J. Neurolymphomatosis in a patient with lymphoblastic lymphoma. *Br J Haematol* 2012;156(6):691 doi: 10.1111/j.1365-2141.2011.09002.x[published Online First: Epub Date]].
 80. Xu L, Zhou Y, Qiu D, Shams S. Fusion PET-CT detection of neurolymphomatosis originating from primary breast lymphoma: A case report and literature review. *Oncol Lett* 2012;4(5):973-75 doi: 10.3892/ol.2012.840[published Online First: Epub Date]].
 81. Yamada S, Tanimoto A, Nabeshima A, et al. Diffuse large B-cell lymphoma presenting with neurolymphomatosis and intravascular lymphoma: a unique autopsy case with diverse neurological symptoms. *Diagn Pathol* 2012;7:94 doi: 10.1186/1746-1596-7-94[published Online First: Epub Date]].
 82. Blioskas S, Tsaligopoulos M, Kyriafinis G, et al. Bilateral secondary neurolymphomatosis of the internal auditory canal nerves: a case report. *Am J Otolaryngol* 2013;34(5):556-8 doi: 10.1016/j.amjoto.2013.04.002[published Online First: Epub Date]].
 83. Choi YJ, Shin JA, Kim YH, et al. Neurolymphomatosis of Brachial Plexus in Patients with Non-Hodgkin's Lymphoma. *Case Rep Oncol Med* 2013;2013:492329 doi: 10.1155/2013/492329[published Online First: Epub Date]].
 84. Hanna R, Di Primio GA, Schweitzer M, Torres C, Sheikh A, Chakraborty S. Progressive neurolymphomatosis with cutaneous disease: response in a patient with mycosis fungoides. *Skeletal Radiol* 2013;42(7):1011-5 doi: 10.1007/s00256-013-1595-6[published Online First: Epub Date]].
 85. Okada M, Takamatsu K, Oebisu N, Nakamura H. Solitary neurolymphomatosis of the brachial plexus mimicking benign nerve sheath tumour: case report. *Br J Neurosurg* 2013;27(3):386-7 doi: 10.3109/02688697.2012.737959[published Online First: Epub Date]].
 86. Ramirez-Zamora A, Morales-Vidal S, Chawla J, Biller J. Autopsy proven peripheral nervous system neurolymphomatosis despite negative bilateral sural nerve biopsy. *Front Neurol* 2013;4:197 doi: 10.3389/fneur.2013.00197[published Online First: Epub Date]].
 87. Salm LP, Van der Hiel B, Stokkel MP. Neurolymphomatosis diagnosed by (18)F-FDG PET-CT. *Clin Nucl Med* 2013;38(6):e261-2 doi: 10.1097/RLU.0b013e318266ce70[published Online First: Epub Date]].
 88. Tanaka H, Yoshino K, Sakaida E, et al. Secondary neurolymphomatosis detected by whole-body diffusion-weighted magnetic resonance imaging: a case report. *J Clin Exp Hematop* 2013;53(3):221-6 doi: 10.3960/jslrt.53.221[published Online First: Epub Date]].

89. Toledano M, Siddiqui MA, Thompson CA, Garza I, Pittock SJ. Teaching NeuroImages: diagnostic utility of FDG-PET in neurolymphomatosis. *Neurology* 2013;81(1):e3 doi: 10.1212/WNL.0b013e318297eef5[published Online First: Epub Date]].
90. Tomita M, Koike H, Kawagashira Y, et al. Clinicopathological features of neuropathy associated with lymphoma. *Brain* 2013;136(Pt 8):2563-78 doi: 10.1093/brain/awt193[published Online First: Epub Date]].
91. Akagi A, Ono K, Hamaguchi T, et al. Neurolymphomatosis exhibiting repeated exacerbation and remission in both the peripheral and central nervous systems. *J Neurol Sci* 2014;345(1-2):267-8 doi: 10.1016/j.jns.2014.07.038[published Online First: Epub Date]].
92. Canh NX, Tan NV, Tung TT, Son NT, Maurea S. (18)F-FDG PET/CT in Neurolymphomatosis: Report of 3 Cases. *Asia Ocean J Nucl Med Biol* 2014;2(1):57-64
93. Del Grande A, Sabatelli M, Luigetti M, et al. Primary multifocal lymphoma of peripheral nervous system: case report and review of the literature. *Muscle Nerve* 2014;50(6):1016-22 doi: 10.1002/mus.24354[published Online First: Epub Date]].
94. Jung YH, Woo IS, Han DJ, Han CW. (18)F-fluoro-2-deoxy-D-glucose positron emission tomography findings of neurolymphomatosis. *Blood Res* 2014;49(2):83 doi: 10.5045/br.2014.49.2.83[published Online First: Epub Date]].
95. Kajary K, Molnar Z, Miko I, Barsi P, Lengyel Z, Szakall S, Jr. Neurolymphomatosis as a late relapse of non-Hodgkin's lymphoma detected by 18F-FDG PET/CT: a case report. *Rev Esp Med Nucl Imagen Mol* 2014;33(1):39-42 doi: 10.1016/j.remnm.2013.03.004[published Online First: Epub Date]].
96. Kamiya-Matsuoka C, Shroff S, Gildersleeve K, Hormozdi B, Manning JT, Woodman KH. Neurolymphomatosis: a case series of clinical manifestations, treatments, and outcomes. *J Neurol Sci* 2014;343(1-2):144-8 doi: 10.1016/j.jns.2014.05.058[published Online First: Epub Date]].
97. Lagarde S, Tabouret E, Matta M, et al. Primary neurolymphomatosis diagnosis and treatment: a retrospective study. *J Neurol Sci* 2014;342(1-2):178-81 doi: 10.1016/j.jns.2014.04.030[published Online First: Epub Date]].
98. Ogawa S, Fukunaga A, Kanata M, et al. Neurolymphomatosis associated with erythrodermic mycosis fungoides. *Acta Derm Venereol* 2014;94(2):227-8 doi: 10.2340/00015555-1684[published Online First: Epub Date]].
99. Padma S, Sundaram PS, Praveen Kumar SL. Primary peripheral neurolymphomatosis mimicking synovial sarcoma: FDG PETCT to the rescue. *J Cancer Res Ther* 2014;10(3):726-9 doi: 10.4103/0973-1482.136038[published Online First: Epub Date]].
100. Peterson J, Caliskan B, Bonyadlou S. Positron emission tomography/computerized tomography imaging of multiple focus of neurolymphomatosis. *Indian J Nucl Med* 2014;29(4):252-3 doi: 10.4103/0972-3919.142632[published Online First: Epub Date]].
101. Ramirez Ocana D, Gutierrez Cardo AL, Gonzalez Diaz L, Hurst K, Espeso de Haro M. [Neurolymphomatosis as initial manifestation of recurrence in lymphoma]. *Rev Esp Med Nucl Imagen Mol* 2014;33(1):50-1 doi: 10.1016/j.remnm.2013.02.003[published Online First: Epub Date]].
102. Sakai N, Ito-Yamashita T, Takahashi G, et al. Primary neurolymphomatosis of the lower cranial nerves presenting as Dysphagia and hoarseness: a case report. *J Neurol Surg Rep* 2014;75(1):e62-6 doi: 10.1055/s-0033-1363505[published Online First: Epub Date]].

103. Shimizu I, Hamano Y, Sato S, et al. Neurolymphomatosis in a patient with extranodal NK/T-cell lymphoma, nasal-type: a case report and literature review. *Intern Med* 2014;53(5):471-5 doi: 10.2169/internalmedicine.53.0262[published Online First: Epub Date]].
104. Tabuchi S, Yoshioka H, Nakayasu H, Watanabe T. Primary Central Nervous System Lymphoma of the Cerebellopontine Angle That Initially Occurred as Neurolymphomatosis of the Acoustic Nerve. *NMC Case Rep J* 2014;1(1):28-32 doi: 10.2176/nmccrj.2013-0353[published Online First: Epub Date]].
105. Yilmaz S, Sager S, Sen F, Halac M. Bilateral trigeminal nerve recurrence of non-hodgkin lymphoma revealed with FDG PET/CT. *Indian J Nucl Med* 2014;29(1):50-2 doi: 10.4103/0972-3919.125778[published Online First: Epub Date]].
106. Zhou WL, Wu HB, Weng CS, et al. Usefulness of 18F-FDG PET/CT in the detection of neurolymphomatosis. *Nucl Med Commun* 2014;35(11):1107-11 doi: 10.1097/MNM.000000000000181[published Online First: Epub Date]].
107. Advani P, Jiang L, Srinivasan S, Foran J. Disseminated extranodal marginal zone lymphoma involving the gastrocnemius muscle with sural neurolymphomatosis. *Ann Hematol* 2015;94(11):1939-40 doi: 10.1007/s00277-015-2453-5[published Online First: Epub Date]].
108. Advani P, Paulus A, Murray P, et al. A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve. *Clin Lymphoma Myeloma Leuk* 2015;15(6):e117-20 doi: 10.1016/j.clml.2014.12.001[published Online First: Epub Date]].
109. Biswal CK, Mittal BR, Shukla J, Vatsa R, Bhattacharya A, Prabhakar S. Fluorothymidine PET/CT in neurolymphomatosis. *Clin Nucl Med* 2015;40(5):e290-2 doi: 10.1097/RLU.0000000000000632[published Online First: Epub Date]].
110. Brandstadter R, Brody J, Morgello S, et al. Primary Neurolymphomatosis Presenting With Polyradiculoneuropathy Affecting One Lower Limb. *J Clin Neuromuscul Dis* 2015;17(1):6-12 doi: 10.1097/CND.000000000000088[published Online First: Epub Date]].
111. Ebihara Y, Ishii N, Akizuki K, et al. [A case of neurolymphomatosis: peripheral neuropathy induced by diffuse large B-cell lymphoma without any abnormal accumulation observed on early positron emission tomography-computed tomography]. *Brain Nerve* 2015;67(2):219-23 doi: 10.11477/mf.1416200116[published Online First: Epub Date]].
112. Gutierrez-Martinez AJ, Malo-de-Molina R, Garcia-Garcia N. [Multiple cranial neuropathy as a manifestation of primary neurolymphomatosis]. *Rev Neurol* 2015;61(8):381-3
113. Lahoria R, Dyck PJ, Macon WR, et al. Neurolymphomatosis: A report of 2 cases representing opposite ends of the clinical spectrum. *Muscle Nerve* 2015;52(3):449-54 doi: 10.1002/mus.24646[published Online First: Epub Date]].
114. Liu Z, Jiang T, Hou N, Jia Y. Peripheral neurolymphomatosis with tracheal asphyxia: a case report and literature review. *BMC Neurol* 2015;15:149 doi: 10.1186/s12883-015-0405-2[published Online First: Epub Date]].
115. Sato M, Furuta M, Hirayanagi K, Nagamine S, Makioka K, Ikeda Y. [A case of neurolymphomatosis presenting extended involvement of spinal nerve roots]. *Rinsho Shinkeigaku* 2015;55(5):333-8 doi: 10.5692/clinicalneuro.15-000615[published Online First: Epub Date]].
116. Shaikh F, Chan AC, Awan O, et al. Diagnostic Yield of FDG-PET/CT, MRI, and CSF Cytology in Non-Biopsiable Neurolymphomatosis as a Herald Sign of Recurrent Non-Hodgkin's Lymphoma. *Cureus* 2015;7(9):e319 doi: 10.7759/cureus.319[published Online First: Epub Date]].

117. Shaikh F, Savells D, Awan O, et al. Quantitative Imaging Analysis of FDG PET/CT Imaging for Detection of Central Neurolymphomatosis in a Case of Recurrent Diffuse B-Cell Lymphoma. *Cureus* 2015;7(11):e379 doi: 10.7759/cureus.379[published Online First: Epub Date]].
118. Sunami Y, Gotoh A, Hamano Y, et al. Various neurological symptoms by neurolymphomatosis as the initial presentation of primary testicular lymphoma. *Case Rep Oncol* 2015;8(1):200-4 doi: 10.1159/000381874[published Online First: Epub Date]].
119. Tong AK, Neo SH, Kok TY. Disseminated Lymphoma Evolving into Neurolymphomatosis during Mid-cycle of Chemotherapy Detected by (18)F-FDG PET/CT. *Ann Acad Med Singap* 2015;44(11):545-7
120. Tsai HH, Chen YF, Hsieh ST, Chao CC. Neurological picture. Neurolymphomatosis as the primary presentation of non-Hodgkin's Lymphoma. *J Neurol Neurosurg Psychiatry* 2015;86(8):929-30 doi: 10.1136/jnnp-2014-308244[published Online First: Epub Date]].
121. Vijayan J, Chan YC, Therimadasamy A, Wilder-Smith EP. Role of combined B-mode and Doppler sonography in evaluating neurolymphomatosis. *Neurology* 2015;85(9):752-5 doi: 10.1212/WNL.0000000000001880[published Online First: Epub Date]].
122. Wang Y, Wang J, Jiang C, Peng Q, Wu M, Ma X. Secondary neurolymphomatosis of spinal nerve roots detected by (1)(8)F-FDG PET/CT: a case report and differential diagnosis of the case. *Hell J Nucl Med* 2015;18(3):261-3 doi: 10.1967/s002449910309[published Online First: Epub Date]].
123. Bruce D, Eagleton H, Subesinghe M. Diagnostic and response assessment FDG PET-CT in neurolymphomatosis. *Clin Case Rep* 2016;4(12):1172-74 doi: 10.1002/ccr3.734[published Online First: Epub Date]].
124. de Jong A, Mous R, van Dongen GA, Hoekstra OS, Nievelstein RA, de Keizer B. (89) Zr-rituximab PET/CT to detect neurolymphomatosis. *Am J Hematol* 2016;91(6):649-50 doi: 10.1002/ajh.24328[published Online First: Epub Date]].
125. Denays R, Baudrez V, Abouhamad P, Dereme T, Milbouw G, Hermanne JP. Plexiform neurolymphomatosis. *Rev Neurol (Paris)* 2016;172(4-5):328-30 doi: 10.1016/j.neurol.2016.02.008[published Online First: Epub Date]].
126. Gammon B, Gammon BR, Kim YH, Kim J. Neurotropic Gamma-Delta T-Cell Lymphoma With CD30-Positive Lymphoid Infiltrates. *Am J Dermatopathol* 2016;38(9):e133-6 doi: 10.1097/DAD.0000000000000560[published Online First: Epub Date]].
127. Gykiere P, Jans L, Degrieck B, Goethals I. Neurolymphomatosis on 18F-FDG PET/CT: Diagnosis and Therapy Response. *Clin Nucl Med* 2016;41(2):142-3 doi: 10.1097/RLU.0000000000000982[published Online First: Epub Date]].
128. He W, Wang W, Gustas C, Malysz J, Kaur D. Isolated sciatic neuropathy as an initial manifestation of a high grade B-cell lymphoma: A case report and literature review. *Clin Neurol Neurosurg* 2016;149:147-53 doi: 10.1016/j.clineuro.2016.07.029[published Online First: Epub Date]].
129. Kinoshita H, Yamakado H, Kitano T, et al. Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases. *J Neurol* 2016;263(9):1719-26 doi: 10.1007/s00415-016-8190-4[published Online First: Epub Date]].
130. Lim AT, Clucas D, Khoo C, Parameswaran BK, Lau E. Neurolymphomatosis: MRI and (18) FDG-PET features. *J Med Imaging Radiat Oncol* 2016;60(1):92-5 doi: 10.1111/1754-9485.12321[published Online First: Epub Date]].

131. Oner AO, Okuyucu K, Alagoz E, Battal B, Arslan N. An Extremely Rare Intersection: Neurolymphomatosis in a Patient with Burkitt Lymphoma Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. *World J Nucl Med* 2016;15(3):209-11 doi: 10.4103/1450-1147.172304[published Online First: Epub Date]].
132. Pham M, Awad M. Lymphoma relapse presenting as neurolymphomatosis. *Asian J Neurosurg* 2016;11(1):73 doi: 10.4103/1793-5482.165783[published Online First: Epub Date]].
133. Scharf EL, Hanson CA, Howard MT, Keegan BM. Serial cerebrospinal fluid examinations to diagnose hematological malignancy causing neurological disease. *J Neurooncol* 2016;129(1):77-83 doi: 10.1007/s11060-016-2140-y[published Online First: Epub Date]].
134. Shree R, Goyal MK, Modi M, et al. The Diagnostic Dilemma of Neurolymphomatosis. *J Clin Neurol* 2016;12(3):274-81 doi: 10.3988/jcn.2016.12.3.274[published Online First: Epub Date]].
135. Sideras PA, Matthews J, Sakib SM, Ofikwu F, Spektor V. Neurolymphomatosis of the peripheral nervous system: a case report and review of the literature. *Clin Imaging* 2016;40(6):1253-56 doi: 10.1016/j.clinimag.2016.08.014[published Online First: Epub Date]].
136. Umeda M, Kondo T, Nishikori M, et al. A case of neurolymphomatosis caused by follicular lymphoma successfully treated with bendamustine. *Clin Case Rep* 2016;4(1):23-5 doi: 10.1002/ccr3.436[published Online First: Epub Date]].
137. Usami M, Murase K, Takada K, et al. [Neurolymphomatosis of the sciatic nerve diagnosed by FDG-PET/CT]. *Rinsho Ketsueki* 2016;57(1):52-5 doi: 10.11406/rinketsu.57.52[published Online First: Epub Date]].
138. Yu Y, Ren M, Qi X. Pathologically proven peripheral neurolymphomatosis. *Neurol India* 2016;64(4):805-7 doi: 10.4103/0028-3886.185354[published Online First: Epub Date]].
139. Yu YX, Liu JY, Yao S. [Diffuse large B-cell lymphoma presenting with neurolymphomatosis: a case report]. *Zhonghua Nei Ke Za Zhi* 2016;55(9):722-3 doi: 10.3760/cma.j.issn.0578-1426.2016.09.014[published Online First: Epub Date]].
140. Briani C, Visentin A, Cavallaro T, et al. Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. *Ann Hematol* 2017;96(1):159-61 doi: 10.1007/s00277-016-2852-2[published Online First: Epub Date]].
141. Bund C, Heimburger C, Trens P, Fohrer C, Kremer S, Namer IJ. FDG PET to Diagnose Neurolymphomatosis in a Case of Triple-Hit B-Cell Lymphoma. *Clin Nucl Med* 2017;42(6):458-60 doi: 10.1097/RLU.0000000000001608[published Online First: Epub Date]].
142. Byun JM, Kim KH, Kim M, et al. Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. *Leuk Lymphoma* 2017;58(11):2624-32 doi: 10.1080/10428194.2017.1312376[published Online First: Epub Date]].
143. Chang GY. Evolution of Neurolymphomatosis to Lymphomatosis Cerebri. *J Clin Neurol* 2017;13(2):203-04 doi: 10.3988/jcn.2017.13.2.203[published Online First: Epub Date]].
144. de Vaugelade C, de Clermont-Gallerande H, Meyer M, et al. FDG PET/CT in Pediatric Neurolymphomatosis. *Clin Nucl Med* 2017;42(5):e255-e57 doi: 10.1097/RLU.0000000000001624[published Online First: Epub Date]].
145. Foo TL, Yak R, Puhaindran ME. Peripheral Nerve Lymphomatosis. *J Hand Surg Asian Pac Vol* 2017;22(1):104-07 doi: 10.1142/S0218810417720042[published Online First: Epub Date]].
146. Gorospe L, Gallego-Rivera JI, Rioja-Martin ME, Chinea-Rodriguez A. Bilateral sciatic nerve neurolymphomatosis: PET/CT findings. *Ann Hematol* 2017;96(6):1059-60 doi: 10.1007/s00277-017-2988-8[published Online First: Epub Date]].

147. Groth CL, Nevel KS, Gwathmey KG, Bafakih F, Jones DE. Splenic marginal zone lymphoma: An indolent malignancy leading to the development of neurolymphomatosis. *Muscle Nerve* 2017;55(3):440-44 doi: 10.1002/mus.25404[published Online First: Epub Date]].
148. Kaulen LD, Foss FM, Fulbright RK, Huttner A, Baehring JM. Neurolymphomatosis of the thoracic sympathetic chain. *Neurology* 2017;89(18):1926-27 doi: 10.1212/WNL.0000000000004600[published Online First: Epub Date]].
149. Khader A, Vineetha M, George M, Manakkad SP, Balakrishnan S, Rajan U. Neurolymphomatosis in Primary Cutaneous CD4+ Pleomorphic Small/Medium-sized T-cell Lymphoma Mimicking Hansen's Disease. *Indian J Dermatol* 2017;62(3):315-17 doi: 10.4103/ijd.IJD_553_16[published Online First: Epub Date]].
150. Khandelwal S, Saxena S, Hansalia DJ. Neurolymphomatosis: A Surreal Presentation of Lymphoma. *Indian J Med Paediatr Oncol* 2017;38(3):287-90 doi: 10.4103/ijmpo.ijmpo_151_16[published Online First: Epub Date]].
151. Laumonerie P, Capek S, Amrami KK, Dyck PJ, Spinner RJ. Targeted fascicular biopsy of the brachial plexus: rationale and operative technique. *Neurosurg Focus* 2017;42(3):E9 doi: 10.3171/2017.1.FOCUS16404[published Online First: Epub Date]].
152. Le Guennec L, Maisonobe T, Choquet S, et al. Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma. *Leuk Lymphoma* 2017;58(3):729-31 doi: 10.1080/10428194.2016.1211277[published Online First: Epub Date]].
153. Noda Y, Sekiguchi K, Tokuoka H, et al. Ultrasonographic findings of proximal median neuropathy: A case series of suspected distal neuralgic amyotrophy. *J Neurol Sci* 2017;377:1-5 doi: 10.1016/j.jns.2017.03.037[published Online First: Epub Date]].
154. Ono Y, Kazuma Y, Ochi Y, Matsuoka R, Imai Y, Ishikawa T. Two Cases of Neurolymphomatosis with Fatal Bilateral Vocal Cord Paralysis that were Diagnosed with (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG PET)/CT. *Intern Med* 2017;56(10):1193-98 doi: 10.2169/internalmedicine.56.6998[published Online First: Epub Date]].
155. Tanimizu M, Kobayashi K. Neurolymphomatosis Appeared Following Primary Central Nervous System Lymphoma. *Intern Med* 2017;56(4):463-64 doi: 10.2169/internalmedicine.56.7238[published Online First: Epub Date]].
156. Trevisan AC, Ribeiro FB, Itikawa EN, et al. 18F-FDG PET/CT/MRI Fusion Images Showing Cranial and Peripheral Nerve Involvement in Neurolymphomatosis. *Indian J Nucl Med* 2017;32(1):77-78 doi: 10.4103/0972-3919.198502[published Online First: Epub Date]].
157. Yi FF, Luo SS, Zhu WH, Zhao CB. Neurolymphomatosis Caused by Nasal-type Extranodal Natural Killer/T-cell Lymphoma. *Chin Med J (Engl)* 2017;130(5):625-26 doi: 10.4103/0366-6999.200547[published Online First: Epub Date]].
158. Asanome A, Kano K, Takahashi K, Saito T, Sawada J, Katayama T. [A case of neurolymphomatosis that was diagnosed by acoustic nerve biopsy]. *Rinsho Shinkeigaku* 2018;58(2):93-99 doi: 10.5692/clinicalneuro.001080[published Online First: Epub Date]].
159. Awis Qarni F, Tai E, Wh WH, Husin A. Homonymous Hemianopia: A Rare Presentation of Secondary Central Nervous System Neurolymphomatosis. *Cureus* 2018;10(5):e2708 doi: 10.7759/cureus.2708[published Online First: Epub Date]].
160. Bjornard KL, Leventaki V, Nichols KE, Sandlund JT, Prockop S, Ehrhardt MJ. Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with

- neurolymphomatosis. *Pediatr Blood Cancer* 2018;65(12):e27415 doi: 10.1002/pbc.27415[published Online First: Epub Date]].
161. Bourque PR, Warman Chardon J, Bryanton M, Toupin M, Burns BF, Torres C. Neurolymphomatosis of the Brachial Plexus and its Branches: Case Series and Literature Review. *Can J Neurol Sci* 2018;45(2):137-43 doi: 10.1017/cjn.2017.282[published Online First: Epub Date]].
 162. Brand C, Pala A, Scheuerle A, et al. [Neurolymphomatosis : Two case reports]. *Nervenarzt* 2018;89(6):701-04 doi: 10.1007/s00115-017-0460-6[published Online First: Epub Date]].
 163. Daher A, Kamiya-Matsuoka C, Woodman K. Patient With 2 Hematologic Malignancies Presenting as Neurolymphomatosis. *J Clin Neuromuscul Dis* 2018;19(3):124-30 doi: 10.1097/CND.000000000000183[published Online First: Epub Date]].
 164. Davidson T, Kedmi M, Avigdor A, et al. FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes. *Leuk Lymphoma* 2018;59(2):348-56 doi: 10.1080/10428194.2017.1352096[published Online First: Epub Date]].
 165. Duchesne M, Roussellet O, Maisonobe T, et al. Pathology of Nerve Biopsy and Diagnostic Yield of PCR-Based Clonality Testing in Neurolymphomatosis. *J Neuropathol Exp Neurol* 2018;77(9):769-81 doi: 10.1093/jnen/nly055[published Online First: Epub Date]].
 166. Haydaroglu Sahin H, Mete A, Pehlivan M. Neurolymphomatosis in non-Hodgkin lymphoma with cranial multineuritis: A case report. *Medicine (Baltimore)* 2018;97(15):e0303 doi: 10.1097/MD.0000000000010303[published Online First: Epub Date]].
 167. Jimenez Zapata HD, Rojas Medina LM, Carrasco Moro R, Martinez Rodrigo A, Garcia-Cosio Piqueras M. Cauda equina syndrome secondary to neurolymphomatosis: Case report and literature review. *Neurocirugia (Astur : Engl Ed)* 2018;29(3):138-42 doi: 10.1016/j.neucir.2017.07.001[published Online First: Epub Date]].
 168. Kobayashi M, Sakai Y, Kariya Y, et al. First pathological report of a de novo CD5-positive diffuse large B-cell lymphoma patient presenting with Guillain-Barre syndrome-like neuropathy due to neurolymphomatosis. *Neuropathology* 2018 doi: 10.1111/neup.12470[published Online First: Epub Date]].
 169. Konishi H, Taguchi Y, Yamamoto M, Nukui T, Dougu N, Nakatsuji Y. [A case of neurolymphomatosis presented as cauda equine syndrome accompanied with M-proteinemia]. *Rinsho Shinkeigaku* 2018;58(4):223-28 doi: 10.5692/clinicalneuro.1001079[published Online First: Epub Date]].
 170. Liu KC, Hennessey MA, McCall CM, Proia AD. Ocular involvement in neurolymphomatosis. *Am J Ophthalmol Case Rep* 2018;10:148-51 doi: 10.1016/j.ajoc.2018.02.023[published Online First: Epub Date]].
 171. Mahmoud RA, Abrams CK. Acute demyelinating neuropathy in a patient with neurolymphomatosis. *BMJ Case Rep* 2018;2018 doi: 10.1136/bcr-2017-222814[published Online First: Epub Date]].
 172. Mustafa R, Klein CJ, Martinez-Thompson J, et al. Recurrent Brachial Neuritis Attacks in Presentation of B-Cell Lymphoma. *Mayo Clin Proc Innov Qual Outcomes* 2018;2(4):382-86 doi: 10.1016/j.mayocpiqo.2018.10.002[published Online First: Epub Date]].
 173. Park HJ, Shin HY, Kim SH, et al. Partial Conduction Block as an Early Nerve Conduction Finding in Neurolymphomatosis. *J Clin Neurol* 2018;14(1):73-80 doi: 10.3988/jcn.2018.14.1.73[published Online First: Epub Date]].

174. Phang I, Craig-McQuaide A, Kinch K, Taylor W. Burkitt's neurolymphomatosis of the trigeminal nerve. *BMJ Case Rep* 2018;2018 doi: 10.1136/bcr-2018-225958[published Online First: Epub Date]].
175. Roy SG, Parida GK, Tripathy S, Das CJ, Kumar R. Active Leprosy Neuritis Detected on FDG PET/CT. *Clin Nucl Med* 2018;43(2):132-33 doi: 10.1097/RLU.0000000000001946[published Online First: Epub Date]].
176. Sasaki R, Ohta Y, Yamada Y, et al. Neurolymphomatosis in the Cauda Equina Diagnosed by an Open Biopsy. *Intern Med* 2018;57(23):3463-65 doi: 10.2169/internalmedicine.1049-18[published Online First: Epub Date]].
177. Schuster NM, Volney SJ, Kamdar MM. Sciatic Lymphoma Mimicking Lumbar Radiculopathy. *Pain Med* 2018;19(10):2091-92 doi: 10.1093/pm/pny153[published Online First: Epub Date]].
178. Uematsu N, Sumi M, Kaiume H, et al. [Neurolymphomatosis due to enteropathy-associated T-cell lymphoma clinically diagnosed by FDG-PET/CT and subsequently confirmed by autopsy]. *Rinsho Ketsueki* 2018;59(1):69-74 doi: 10.11406/rinketsu.59.69[published Online First: Epub Date]].
179. Bourque PR, Sampaio ML, Warman-Chardon J, Samaan S, Torres C. Neurolymphomatosis of the lumbosacral plexus and its branches: case series and literature review. *BMC Cancer* 2019;19(1):1149 doi: 10.1186/s12885-019-6365-y[published Online First: Epub Date]].
180. Chague P, Phan CM, Lapusan S, Zhang-Yin J, Cottureau AS. (18)F-FDG PET/CT imaging findings of extensive neurolymphomatosis as a relapse of diffuse large B cell lymphoma. *Diagn Interv Imaging* 2019;100(9):527-28 doi: 10.1016/j.diii.2019.02.006[published Online First: Epub Date]].
181. DeBoer SR, Lesche S, Rodriguez FJ, Ostrow LW. Teaching NeuroImages: Neurolymphomatosis. *Neurology* 2019;93(12):e1229-e30 doi: 10.1212/WNL.0000000000008131[published Online First: Epub Date]].
182. DeVries AH, Howe BM, Spinner RJ, Broski SM. B-cell peripheral neurolymphomatosis: MRI and (18)F-FDG PET/CT imaging characteristics. *Skeletal Radiol* 2019;48(7):1043-50 doi: 10.1007/s00256-019-3145-3[published Online First: Epub Date]].
183. Ganeshalingam R, Roach P, Schembri GP. Diffuse Large B-Cell Lymphoma Recurring as Neurolymphomatosis on FDG PET/CT. *Clin Nucl Med* 2019;44(2):145-47 doi: 10.1097/RLU.0000000000002388[published Online First: Epub Date]].
184. Iacobellis F, Di Serafino M, Blasio R, Barbuto L, Pezzullo F, Romano L. Secondary Neurolymphomatosis of the Radial Nerve: A Diagnostic Challenge. *Am J Case Rep* 2019;20:1652-58 doi: 10.12659/AJCR.916961[published Online First: Epub Date]].
185. Kobayashi H, Abe Y, Miura D, et al. Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis. *Int J Hematol* 2019;109(3):286-91 doi: 10.1007/s12185-018-02586-7[published Online First: Epub Date]].
186. Li H, Luo SS, Zhao CB. Neurolymphomatosis caused by diffuse large B-cell lymphoma presenting as isolated brachial plexopathy. *Chin Med J (Engl)* 2019;132(22):2762-64 doi: 10.1097/CM9.0000000000000514[published Online First: Epub Date]].
187. Li V, Jaunmuktane Z, Cwynarski K, Carr A. Diagnostic delay in a case of T-cell neurolymphomatosis. *BMJ Case Rep* 2019;12(12) doi: 10.1136/bcr-2019-232538[published Online First: Epub Date]].

188. Matsue K, Abe Y, Narita K, et al. Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years. *Br J Haematol* 2019;187(3):328-36 doi: 10.1111/bjh.16081[published Online First: Epub Date].
189. Mori Y, Yamamoto K, Ohno A, Fukunaga M, Nishikawa A. Primary Central Nervous System Lymphoma with Peripheral Nerve Involvement: Case Report. *Cureus* 2019;11(9):e5675 doi: 10.7759/cureus.5675[published Online First: Epub Date].
190. Narita K, Kobayashi H, Kitadate A, et al. Neurolymphomatosis of the sciatic and tibial nerves as an initial presentation of lung diffuse large B cell lymphoma detected by positron emission tomography/computed tomography. *Int J Hematol* 2019;110(4):385-86 doi: 10.1007/s12185-019-02705-y[published Online First: Epub Date].
191. Padilha IG, Fischer T, Pacheco FT, Da Rocha AJ. Brachial and sacral plexus neurolymphomatosis - unusual regions for disease relapses. *Arq Neuropsiquiatr* 2019;77(11):832-33 doi: 10.1590/0004-282X20190104[published Online First: Epub Date].
192. Puffer RC, Dyck PJB, Paul P, Broski SM, Amrami KK, Spinner RJ. Putative mechanisms for spread and transformation of cutaneous T-cell lymphoma to neurolymphomatosis. *Muscle Nerve* 2019;60(5):E30-E33 doi: 10.1002/mus.26670[published Online First: Epub Date].
193. Rai W, Olcese V, Elsheikh B, Stino AM. Horner's Syndrome as Initial Manifestation of Possible Brachial Plexopathy Neurolymphomatosis. *Front Neurol* 2019;10:4 doi: 10.3389/fneur.2019.00004[published Online First: Epub Date].
194. Sato H, Hiroshima S, Anei R, Kamada K. Primary neurolymphomatosis of the trigeminal nerve. *Br J Neurosurg* 2019;1-4 doi: 10.1080/02688697.2019.1568391[published Online First: Epub Date].
195. Sosa-Albacete F, Pappolla A, Hem S, et al. [Primary neurolymphomatosis in the cauda equina as the initial symptom of human immunodeficiency virus]. *Rev Neurol* 2019;69(7):301-02 doi: 10.33588/rn.6907.2019244[published Online First: Epub Date].
196. Tai R, Maingard J, Nambiar M, Lim K. High-grade B-cell lymphoma relapse presenting as neurolymphomatosis of the median nerve. *BMJ Case Rep* 2019;12(3) doi: 10.1136/bcr-2018-228742[published Online First: Epub Date].
197. Yaseen MT, Aziz PAA, Siddique K, Tariq TA. Neurolymphomatosis of the Sciatic and Tibial Nerves. *J Coll Physicians Surg Pak* 2019;29(12):S86-S88 doi: 10.29271/jcpsp.2019.12.S86[published Online First: Epub Date].
198. Campagnolo M, Cacciavillani M, Cavallaro T, et al. Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: Suggestive features and diagnostic challenges. *J Peripher Nerv Syst* 2020;25(3):312-15 doi: 10.1111/jns.12401[published Online First: Epub Date].
199. Facchinelli D, Ciliberti E, Stussi G, Ceriani L, Zucca E. Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS. *Hematol Oncol* 2020;38(2):197-200 doi: 10.1002/hon.2698[published Online First: Epub Date].
200. Fatima N, Zaman MU, Zaman A, Zaman SU. Neurolymphomatosis - Rare presentation in non-Hodgkin's lymphoma: The role of (18)F-fluorodeoxyglucose positron-emission tomography and computerized tomography imaging. *World J Nucl Med* 2020;19(2):159-61 doi: 10.4103/wjnm.WJNM_22_19[published Online First: Epub Date].

201. Fitzgerald L, Stephens DM. Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. *Clin Lymphoma Myeloma Leuk* 2020;20(4):e201-e04 doi: 10.1016/j.clml.2020.01.012[published Online First: Epub Date]].
202. Keddie S, Nagendran A, Cox T, et al. Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes. *Muscle Nerve* 2020;62(5):617-25 doi: 10.1002/mus.27045[published Online First: Epub Date]].
203. Lorance DK, Allison JB, Gardner JA, Waheed W. Protean Manifestations and Diagnostic Challenges Including Discordance Between Electrodiagnostic-Radiologic Studies in Neurolymphomatosis. *Neurologist* 2020;25(1):4-9 doi: 10.1097/NRL.000000000000245[published Online First: Epub Date]].
204. Murthy NK, Amrami KK, Spinner RJ. Circumdural extension of perineural spread leading to bilateral disease in neurolymphomatosis. *Acta Neurochir (Wien)* 2020;162(12):3197-200 doi: 10.1007/s00701-020-04417-3[published Online First: Epub Date]].
205. Murthy NK, Hebert-Blouin MN, Capek S, Prasad NK, Amrami KK, Spinner RJ. Understanding the Pathognomonic Tumefactive Appearance of Neurolymphomatosis: A Unifying Theory of Neurolymphoma. *World Neurosurg* 2020;141:e490-e97 doi: 10.1016/j.wneu.2020.05.228[published Online First: Epub Date]].
206. Murthy NK, Sharma M, Spinner RJ. Primary peripheral nerve tumors associated with nerve-territory herpes zoster. *Acta Neurochir (Wien)* 2020;162(5):1147-51 doi: 10.1007/s00701-020-04292-y[published Online First: Epub Date]].
207. Nepal P, Batchala PP, Rehm PK, Fadul CE. Diffuse large B-cell lymphoma relapse presenting as extensive neurolymphomatosis. *Neuroradiol J* 2020;33(3):230-35 doi: 10.1177/1971400920924799[published Online First: Epub Date]].
208. Nishikawara M, Kawakami T, Sakai H, et al. Magnetic Resonance Imaging-negative, Rituximab-resistant Neurolymphomatosis as a Paradoxical Presentation of Relapsed Primary Adrenal Lymphoma. *Intern Med* 2020;59(11):1437-43 doi: 10.2169/internalmedicine.4085-19[published Online First: Epub Date]].
209. Pan Q, Luo Y. Recurrence of nasal type NK/T cell lymphoma presenting as neurolymphomatosis on 18F-FDG PET/CT: A case report and literature review. *Medicine (Baltimore)* 2020;99(1):e18640 doi: 10.1097/MD.00000000000018640[published Online First: Epub Date]].
210. Seegobin K, Alhaj Moustafa M, Fischer D, et al. Systemic ALK-positive anaplastic large cell lymphoma with bilateral optic neurolymphomatosis resulting in permanent blindness. *Clin Case Rep* 2020;8(12):2629-33 doi: 10.1002/ccr3.3231[published Online First: Epub Date]].
211. Shima T, Tsujino A. [Neurolymphomatosis Mimicking Inflammatory Neuropathy with Slight FDG Uptake on PET/CT and Distinct MRI Abnormalities in the Brachial Plexus: A Case Report]. *Brain Nerve* 2020;72(9):987-92 doi: 10.11477/mf.1416201632[published Online First: Epub Date]].
212. Singh SS, Mittal BR, Kumar R, Singh H, Balaini N, Goyal M. Primary Central Nervous System Lymphoma With Diffuse Neurolymphomatosis Involving Multiple Cranial and Spinal Nerve Roots. *Clin Nucl Med* 2020;45(6):e285-e87 doi: 10.1097/RLU.0000000000003018[published Online First: Epub Date]].
213. Switlyk MD, Skeie AT, Lund-Iversen M, Ostenstad B. Magnetic resonance imaging and (18)F-fluorodeoxyglucose positron emission tomography/computed tomography findings in

- neurolymphomatosis: an uncommon presentation of diffuse large B cell lymphoma. *Ann Hematol* 2020;99(1):203-05 doi: 10.1007/s00277-019-03850-4[published Online First: Epub Date]].
214. Yadav D, Angamuthu M, Subudhi TK, Das CJ, Kumar R. PET/CT in Evaluation of Low Backache Due to Sacral Nerve Root Involvement: Inflammatory and Malignant Involvement. *Clin Nucl Med* 2020;45(6):e299-e300 doi: 10.1097/RLU.0000000000003021[published Online First: Epub Date]].
215. Alazawi S, Elomri H, Taha R, et al. Neurolymphomatosis of the median nerve, optic nerve, L4 spinal nerve root and cauda equina in patients with B-cell malignancies: a case series. *J Med Case Rep* 2021;15(1):133 doi: 10.1186/s13256-021-02714-8[published Online First: Epub Date]].
216. Campagnolo M, Cacciavillani M, Briani C. Heterogeneous clinical and imaging findings and long-term prognosis in patients with neurolymphomatosis. *Muscle Nerve* 2021;63(3):E24-E26 doi: 10.1002/mus.27154[published Online First: Epub Date]].
217. Fritzhand SJ, Esmaeli B, Sun J, Debnam JM. Primary disease sites and patterns of spread in cases of neurolymphomatosis in the orbit associated with lymphoma. *Cancer Imaging* 2021;21(1):39 doi: 10.1186/s40644-021-00409-3[published Online First: Epub Date]].
218. Hamaguchi M, Kokubun N, Matsuda H, et al. A case report of secondary neurolymphomatosis showing selective nerve infiltration and massive lumbar plexus enlargement. *BMC Neurol* 2021;21(1):296 doi: 10.1186/s12883-021-02330-5[published Online First: Epub Date]].
219. Jeong J, Kim SW, Sung DH. Neurolymphomatosis: a single-center experience of neuromuscular manifestations, treatments, and outcomes. *J Neurol* 2021;268(3):851-59 doi: 10.1007/s00415-020-10202-0[published Online First: Epub Date]].
220. Khurana A, Dalland JC, Young JR, Inwards DJ, Paludo J. Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis. *Am J Hematol* 2021;96(8):E298-E301 doi: 10.1002/ajh.26233[published Online First: Epub Date]].
221. Khurana A, Novo M, Nowakowski GS, et al. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. *Blood Adv* 2021;5(5):1379-87 doi: 10.1182/bloodadvances.2020003666[published Online First: Epub Date]].
222. Kim KT, Kim SI, Do YR, Jung HR, Cho JH. Sciatic nerve neurolymphomatosis as the initial presentation of primary diffuse large B-cell lymphoma: a rare cause of leg weakness. *Yeungnam Univ J Med* 2021;38(3):258-63 doi: 10.12701/yujm.2021.00983[published Online First: Epub Date]].
223. Kuhlman JJ, Alhaj Moustafa M, Gupta V, Jiang L, Tun HW. Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review. *J Blood Med* 2021;12:645-52 doi: 10.2147/JBM.S325264[published Online First: Epub Date]].
224. Lee YC, Huang GS, Chang WC, Hsu YC. Fried egg sign: A typical ultrasonography feature of neurolymphomatosis. *J Clin Ultrasound* 2021;49(8):878-80 doi: 10.1002/jcu.23029[published Online First: Epub Date]].
225. Makranz C, Arkadir D, Nachmias B, et al. Neurological misdiagnoses of lymphoma. *Neurol Sci* 2021;42(5):1933-40 doi: 10.1007/s10072-020-04724-8[published Online First: Epub Date]].
226. Negre Buso M, Balliu Collgros E, Rubio Rodriguez A, Pelaez Hernandez I, Mestre Fusco A, Roncero Vidal JM. Utility of the (18)F-FDG PET/CT in the diagnosis of the

- neurolymphomatosis: A case report. *Rev Esp Med Nucl Imagen Mol (Engl Ed)* 2021;40(5):328-31 doi: 10.1016/j.remnie.2020.09.017[published Online First: Epub Date]].
227. Nishida K, Takenaka Y, Yamasaki H, Futamura N. Garcin Syndrome in a Patient With Neurolymphomatosis. *Neurology* 2021 doi: 10.1212/WNL.0000000000012485[published Online First: Epub Date]].
228. Rastogi P, Singh H, Gupta P, Bal A, Dutta U, Gupta N. Extra-hepatic biliary obstruction due to diffuse large B-cell lymphoma: an autopsy case report with unattended yet significant pathologies. *Clin J Gastroenterol* 2021;14(1):269-74 doi: 10.1007/s12328-020-01252-y[published Online First: Epub Date]].
229. Raut TP, Bhatt M, Hastak M, et al. Neurolymphomatosis as a Presenting Feature of Primary Testicular Lymphoma. *Ann Indian Acad Neurol* 2021;24(2):269-72 doi: 10.4103/aian.AIAN_304_20[published Online First: Epub Date]].
230. Sheng S, Sharma R, Samant R, Yuan J, Nalleballe K, Kapoor N. Isolated primary neurolymphomatosis with cranial multineuritis: a case presentation. *Neurol Sci* 2021;42(3):1223-26 doi: 10.1007/s10072-020-04806-7[published Online First: Epub Date]].
231. Barahona D, Adlerstein I, Donoso J, Mercado F. Sciatic and median nerve neurolymphomatosis as initial presentation of B-cell lymphoma. *Radiologia (Engl Ed)* 2022;64(3):266-69 doi: 10.1016/j.rxeng.2020.10.003[published Online First: Epub Date]].

Cranial Nerves(226)	
Unspecified cranial nerves	129
Olfactory	1
Optic Nerve	4
Oculomotor nerve	12
Trochlear nerve	1
Trigeminal nerve	32
Mandibular nerve	1
Abducens nerve	5
Facial nerves	16
Mental nerve	2
Temporal nerve	1
Vestibulocochlear (acoustic)	7
Vagus nerve	5
Hypoglossal nerve	1
Glossopharyngeal	3
Infratrochlear nerve	1
Pharyngeal/vagal nerve	1
Ciliary nerve	1
Internal auditory canal nerve	1
7th and 8th nerve complex	1
7th and 8th nerve complex	1
Neural Plexus(290)	
Unspecified Peripheral nerves	27
Brachial plexus(139)	
Brachial plexus	133
Axillary nerve	5
Suprascapular nerve	1
Lumbosacral plexus nerves(151)	
Lumbosacral plexus nerves	71
Lumbar plexus	17
Obturator nerve	1
Piriformis nerve	1
Cauda Equina	59
Iliac nerves	1
Gluteal nerve	1
Spinal Nerves(241)	
Unspecified Spinal nerves	45
Lumbar and sacral nerve roots(92)	
Lumbar nerves (L)	37
Sacral (S)	50
S1	1
S1-S3	2
S2	1
Coccygeal	1
Lumbar & sacral nerve roots(61)	
Cervical spinal nerves (C)	54
C4/5	1
C5/6	1
C8	5
Thoracic nerve roots(43)	
Thoracic nerves	38
T8-9	1
T12-L1	0
T12-L5	1
Intercostal	3
Peripheral Nerves(338)	
Distal upper extremities nerves(44)	
Median Nerve	27
Anterior interosseous nerve	1
Ulnar nerve	12
Radial nerve	4
Posterior cutaneous nerve of forearm	0
Distal lower extremity nerves(294)	
Saphenous nerve	3
Femoral nerve	30
Sciatic	120
Peroneal nerve	17
Fibular nerves	1
Popliteal nerve	2
Sural nerve	15
Tibial (shin)	25
Plantar nerves	0
Unspecified neural plexus	81
Other nerves(8)	
Other nerves	8

Supplemental Table 2: Lists of peripheral nerve involvement.

Supplemental Table 3: Lists of lymphoma histologies. ALCL, anaplastic large cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; IVL, intravascular lymphomatosis; MALT, mucosa-assisted lymphoid tissue; NK, natural killer.

B-Cell lymphomas(689)	
Unspecified B-cell	18
Diffuse large B-cell	360
Follicular	51
CLL/SLL	10
Mantle cell	51
Marginal zone	50
Burkitt	13
Lymphoplasmacytic	53
MALT	5
High-grade B-cell	10
Low-grade B-cell	46
Intermediate & triple-hit B-cell	3
B acute lymphoblastic leukemia	1
IVL	18
Plasma cell leukemia	1
T-cell lymphomas(91)	
T lymphoblastic lymphoma/leukemia	8
Peripheral T-cell	46
Cutaneous T-cell	4
Adult T-cell leukemia/lymphoma	2
Extranodal NK/T-cell* (lymphoma, nasal type)	8
ALCL	2
Unspecified T-cell	14
Enteropathy-associated T-cell	1
T-cell acute lymphocytic leukemia	1
Other(5)	
Acute nonlymphocytic leukemia	2
Acute myelogenous leukemia	2
Histiocytic lymphoma	1

Supplemental Table 4: Decade analysis of (A) OS, (B) treatment 1 to progression, (C) symptom onset to diagnosis, and (D) symptom onset to death periods.

Decade Analysis						
Overall Survival						
Decades	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
≤1990	8	0	0.25	0.707106781	0	1.664213562
1991-2000	14	0.5	7.535714286	22.11374815	0	51.76321058
2001-2010	93	10	10.22768421	12.6038322	0	35.43534861
2011-2020	248	8	14.76141129	19.952725	0	54.66686129
2021-2022	50	26.2	73.288	58.07474649	0	189.437493
Time from Treatment 1 to Progression						
Decades	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
≤1990	0	N/A	N/A	N/A	N/A	N/A
1991-2000	1	2	2	N/A	N/A	N/A
2001-2010	4	2	4.1875	5.304773793	0	14.79704759
2011-2020	49	6.4	9.305918367	11.57894244	0	32.46380324
2021-2022	40	36	28.61	11.04609921	6.517801586	50.70219841
Time from Symptom Onset to Diagnosis						
Decades	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
≤1990	1	6	6	N/A	N/A	N/A
1991-2000	N/A	N/A	N/A	N/A	N/A	N/A
2001-2010	20	2	9.2	17.81143926	0	44.82287851
2011-2020	81	3	7.821851852	14.76708224	0	37.35601632
2021-2022	7	4	18.78571429	34.62881404	0	88.04334237
Time from Symptom Onset to Death						
Decades	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
≤1990	8	0	1	2.138089935	0	5.276179871
1991-2000	14	0.5	7.535714286	22.11374815	0	51.76321058
2001-2010	95	10	12.16136842	19.06360019	0	50.28856881
2011-2020	266	8.75	16.1443609	21.13840025	0	58.4211614
2021-2022	52	26.2	72.99807692	57.50248585	0	188.0030486
NA= Not Available						

Supplemental Table 5: Analysis of various treatments on (A) OS, (B) treatment 1 to progression, (C) symptom onset to diagnosis, and (D) symptom onset to death periods.

5A

Overall Survival						
Types of treatment	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Rituximab & R-CHOP	125	16.25	32.472	44.37503757	0	121.2220751
HD-MTX	81	18.5	37.22098765	47.24362697	0	131.7080416
Radiation	79	6.885	11.70594937	17.20808429	0	46.12211735
HD-MTX + rituximab	40	19	19.5	11.97914855	0	43.4582971
Transplant	32	25.4	58.5915625	55.94084605	0	170.4732546
HD-MTX + transplant	12	25.4	50.61666667	52.40520991	0	155.4270865
Rituximab + transplant	11	23.65	60.87272727	60.21908235	0	181.310892
Corticosteroids	6	12	12.66666667	6.047431568	0.57180353	24.7615298
HD-MTX + rituximab + transplant	5	138	88.9	69.22746324	0	227.3549265
Kruskal-Wallis chi-squared = 63.493	df = 8	p value = 9.578e-11				
Pair	Z score	Bonferroni adjusted p value				
Radiation vs. Transplant	-6.093421218	1.98941E-08				
HD-MTX vs. Radiation	5.419037395	1.07857E-06				
Radiation vs. Rituximab & R-CHOP	-4.584609307	8.18705E-05				
HD-MTX + transplant vs. Radiation	4.101924519	0.00073751				
HD-MTX + rituximab vs. Radiation	4.043568706	0.000947587				
Radiation vs. Rituximab + transplant	-3.951242233	0.001399438				
HD-MTX + rituximab + transplant vs. Radiation	3.413612016	0.0115394				
Rituximab & R-CHOP vs. Transplant	-3.118820434	0.03268379				
HD-MTX + rituximab vs. Transplant	-2.075083322	0.6836186				
HD-MTX + transplant vs. Rituximab & R-CHOP	2.024837769	0.7719125				
HD-MTX vs. Transplant	-2.01125314	0.7973771				
HD-MTX + rituximab + transplant vs. Rituximab & R-CHOP	2.006793363	0.8058901				
Corticosteroids vs. Transplant	-1.993593993	0.8197942				
Corticosteroids vs. HD-MTX + rituximab + transplant	-1.960143547	0.8996223				
Rituximab & R-CHOP vs. Rituximab + transplant	-1.947930314	0.9254902				
Corticosteroids vs. HD-MTX	-1.109989084	1				
Corticosteroids vs. HD-MTX + rituximab	-0.907786497	1				
HD-MTX vs. HD-MTX + rituximab	0.373650378	1				
HD-MTX vs. HD-MTX + rituximab + transplant	-1.556588261	1				
HD-MTX + rituximab vs. HD-MTX + rituximab + transplant	-1.664410425	1				
Corticosteroids vs. HD-MTX + transplant	-1.767243395	1				
HD-MTX vs. HD-MTX + transplant	-1.338376601	1				
HD-MTX + rituximab vs. HD-MTX + transplant	-1.477166519	1				
HD-MTX + rituximab + transplant vs. HD-MTX + transplant	0.569809304	1				
Corticosteroids vs. Radiation	0.914490685	1				
Corticosteroids vs. Rituximab & R-CHOP	-0.650076212	1				
HD-MTX vs. Rituximab & R-CHOP	1.387758267	1				
HD-MTX + rituximab vs. Rituximab & R-CHOP	0.692172641	1				
Corticosteroids vs. Rituximab + transplant	-1.74244955	1				
HD-MTX vs. Rituximab + transplant	-1.290537126	1				
HD-MTX + rituximab vs. Rituximab + transplant	-1.430148019	1				
HD-MTX + rituximab + transplant vs. Rituximab + transplant	0.561033981	1				
HD-MTX + transplant vs. Rituximab + transplant	-0.001688781	1				
HD-MTX + rituximab + transplant vs. Transplant	0.61833954	1				
HD-MTX + transplant vs. Transplant	-0.017589872	1				
Rituximab + transplant vs. Transplant	-0.015018806	1				

Time from Treatment 1 to Progression						
Types of treatment	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Rituximab & R-CHOP	51	36	23.431	15.01322302	0	53.45744605
HD-MTX	45	36	24.75340909	14.62797387	0	54.00935683
HD-MTX + rituximab	31	36	32.06666667	11.31299567	9.440675332	54.692658
Transplant	19	11	17.25555556	11.0250003	0	39.30555615
Radiation	14	9.4	7.861538462	3.521741993	0.818054475	14.90502245
Rituximab + transplant	7	36	26.5	16.47888259	0	59.45776518
HDMTX + transplant	6	28.4	29.92	14.17072771	1.578544582	58.26145542
Corticosteroids	1	13	N/A	8.485281374	N/A	N/A
HD-MTX + rituximab + transplant	0	N/A	N/A	N/A	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-square d=26.8		df = 7	p value = 0.0003621			
Pair	Z score	Bonferroni adjusted p value				
HD-MTX + rituximab vs. Radiation	4.9307755	1.14665E-05				
HD-MTX vs. Radiation	3.6202112	0.004121077				
Radiation vs. Rituximab & R-CHOP	-3.3744642	0.01035433				
HD-MTX + rituximab vs. Transplant	3.0069485	0.03694382				
HD-MTX + rituximab vs. Rituximab & R-CHOP	2.5194367	0.1645599				
HDMTX + transplant vs. Radiation	2.4217916	0.2162189				
Radiation vs. Rituximab + transplant	-2.2129991	0.3765679				
HD-MTX vs. HD-MTX + rituximab	-2.0773454	0.5287757				
Radiation vs. Transplant	-2.0204051	0.6067794				
Corticosteroids vs. HD-MTX	-0.4078558	1				
Corticosteroids vs. HD-MTX + rituximab	-0.880889	1				
Corticosteroids vs. HDMTX + transplant	-0.4526959	1				
HD-MTX vs. HDMTX + transplant	-0.17671	1				
HD-MTX + rituximab vs. HDMTX + transplant	0.9103312	1				
Corticosteroids vs. Radiation	0.669256	1				
Corticosteroids vs. Rituximab & R-CHOP	-0.3202304	1				
HD-MTX vs. Rituximab & R-CHOP	0.4395543	1				
HDMTX + transplant vs. Rituximab & R-CHOP	0.38425	1				
Corticosteroids vs. Rituximab + transplant	-0.3102524	1				
HD-MTX vs. Rituximab + transplant	0.1986457	1				
HD-MTX + rituximab vs. Rituximab + transplant	1.3461263	1				
HDMTX + transplant vs. Rituximab + transplant	0.2827251	1				
Rituximab & R-CHOP vs. Rituximab + transplant	-0.0208117	1				
Corticosteroids vs. Transplant	-0.0184066	1				
HD-MTX vs. Transplant	1.4424866	1				
HDMTX + transplant vs. Transplant	1.003822	1				
Rituximab & R-CHOP vs. Transplant	1.1355556	1				
Rituximab + transplant vs. Transplant	0.7074415	1				

5C

Time from Symptom Onset to Diagnosis						
Types of treatment	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Rituximab & R-CHOP	35	3	11.02941176	20.3533469	0	51.73610557
Radiation	22	2.566666667	8.434126984	10.9523765	0	30.33887998
HD-MTX	16	3.25	5.5	5.755751599	0	17.0115032
Transplant	8	5.5	18.85714286	30.25768956	0	79.37252199
HD-MTX + rituximab	8	4	5.857142857	4.841946349	0	15.54103555
HD-MTX + transplant	4	8	9.666666667	5.93295879	0	21.53258425
Rituximab + transplant	3	8	5.2	45.90842334	0	143.8168467
Corticosteroids	1	6	N/A	3.53533906	N/A	N/A
HD-MTX + rituximab + transplant	1	8	N/A	4.949747468	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-squared = 3.9978						
		df = 8	p value = 0.8573			
Pair	Z score	Bonferroni adjusted p value				
Corticosteroids vs. HD-MTX	0.40138776	1				
Corticosteroids vs. HD-MTX + rituximab	0.41719656	1				
HD-MTX vs. HD-MTX + rituximab	0.06642472	1				
Corticosteroids vs. HD-MTX + rituximab + transplant	-0.23780204	1				
HD-MTX vs. HD-MTX + rituximab + transplant	-0.72764947	1				
HD-MTX + rituximab vs. HD-MTX + rituximab + transplant	-0.73426595	1				
Corticosteroids vs. HD-MTX + transplant	-0.25330394	1				
HD-MTX vs. HD-MTX + transplant	-1.24673035	1				
HD-MTX + rituximab vs. HD-MTX + transplant	-1.18507326	1				
HD-MTX + rituximab + transplant vs. HD-MTX + transplant	0.04749449	1				
Corticosteroids vs. Radiation	0.44458025	1				
HD-MTX vs. Radiation	0.12427102	1				
HD-MTX + rituximab vs. Radiation	0.02923084	1				
HD-MTX + rituximab + transplant vs. Radiation	0.77349095	1				
HD-MTX + transplant vs. Radiation	1.35730763	1				
Corticosteroids vs. Rituximab & R-CHOP	0.31015736	1				
HD-MTX vs. Rituximab & R-CHOP	-0.328663	1				
HD-MTX + rituximab vs. Rituximab & R-CHOP	-0.32649327	1				
HD-MTX + rituximab + transplant vs. Rituximab & R-CHOP	0.64175646	1				
HD-MTX + transplant vs. Rituximab & R-CHOP	1.13255192	1				
Radiation vs. Rituximab & R-CHOP	-0.51461541	1				
Corticosteroids vs. Rituximab + transplant	-0.16350699	1				
HD-MTX vs. Rituximab + transplant	-0.35770468	1				
HD-MTX + rituximab vs. Rituximab + transplant	-0.93249986	1				
HD-MTX + rituximab + transplant vs. Rituximab + transplant	0.12773984	1				
HD-MTX + transplant vs. Rituximab + transplant	0.12359967	1				
Radiation vs. Rituximab + transplant	-1.04535849	1				
Rituximab & R-CHOP vs. Rituximab + transplant	-0.83672035	1				
Corticosteroids vs. Transplant	0.04171966	1				
HD-MTX vs. Transplant	-0.85330212	1				
HD-MTX + rituximab vs. Transplant	-0.7965068	1				
HD-MTX + rituximab + transplant vs. Transplant	0.35878904	1				
HD-MTX + transplant vs. Transplant	0.53472818	1				
Radiation vs. Transplant	-0.99384848	1				
Rituximab & R-CHOP vs. Transplant	-0.68976544	1				
Rituximab + transplant vs. Transplant	0.3442406	1				

5D

Time from Symptom Onset to Death						
Types of treatment	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Rituximab & R-CHOP	125	18	34.572	44.22640267	0	123.0248053
HD-MTX	81	20.75	38.3382716	46.8522835	0	132.0428386
Radiation	79	8.75	13.72008439	18.48971358	0	50.69951155
HD-MTX+ rituximab	40	25.4	61.445	56.67639946	0	174.7977989
Transplant	32	25.4	59.8728125	55.18110317	0	170.2350188
HD-MTX+ transplant	12	25.4	53.7	51.05744251	0	155.814885
Rituximab +transplant	11	20.5	61.78181818	59.61165993	0	181.005138
Corticosteroids	6	13	13.66666667	6.187545094	1.291576479	26.04175685
HD-MTX+ rituximab + transplant	5	79.25	90.5	67.8481761	0	226.1963522
Kruskal-Wallis chi-squared =69.849	df = 8	p value =5.267e-12				
Pair	Z score	Bonferroni adjusted p value				
HD-MTX+ rituximab - Radiation	6.35409211	3.7739E-09				
Radiation - Transplant	-5.69482547	2.22297E-07				
HD-MTX - Radiation	4.89382139	1.78014E-05				
Radiation - Rituximab & R-CHOP	-4.38362727	0.000210095				
HD-MTX+ transplant - Radiation	4.03225436	0.000994398				
Radiation - Rituximab +transplant	-3.66143811	0.004514462				
HD-MTX+ rituximab + transplant - Radiation	3.38964744	0.01259686				
HD-MTX+ rituximab - Rituximab & R-CHOP	3.31940784	0.01623754				
Rituximab & R-CHOP - Transplant	-2.84304368	0.0804329				
HD-MTX - HD-MTX+ rituximab	-2.37627711	0.3147898				
Corticosteroids - HD-MTX+ rituximab	-2.2445939	0.4462959				
Corticosteroids - HD-MTX+ rituximab +transplant	-2.16793809	0.5429412				
Corticosteroids - Transplant	-2.11952381	0.612832				
HD-MTX+ transplant - Rituximab & R-CHOP	2.04899789	0.7283218				
HD-MTX+ rituximab + transplant - Rituximab & R-CHOP	2.04590106	0.7337899				
HD-MTX - Transplant	-2.00899026	0.801687				
Corticosteroids - HD-MTX+ transplant	-1.99782643	0.8232387				
Corticosteroids - HD-MTX	-1.23720922	1				
HD-MTX - HD-MTX+ rituximab + transplant	-1.71283319	1				
HD-MTX+ rituximab - HD-MTX+ rituximab +transplant	-0.69585722	1				
HD-MTX - HD-MTX+ transplant	-1.5370861	1				
HD-MTX+ rituximab - HD-MTX+ transplant	-0.04932722	1				
HD-MTX+ rituximab + transplant - HD-MTX+ transplant	0.58959985	1				
Corticosteroids - Radiation	0.5912616	1				
Corticosteroids - Rituximab & R-CHOP	-0.90846787	1				
HD-MTX - Rituximab & R-CHOP	1.00803312	1				
Corticosteroids - Rituximab + transplant	-1.8283826	1				
HD-MTX - Rituximab + transplant	-1.25875084	1				
HD-MTX+ rituximab - Rituximab +transplant	0.16078029	1				
HD-MTX+ rituximab +transplant - Rituximab +transplant	0.71346128	1				
HD-MTX+ transplant - Rituximab +transplant	0.17002852	1				
Rituximab & R-CHOP - Rituximab +transplant	-1.74329176	1				
HD-MTX+ rituximab - Transplant	0.16759049	1				
HD-MTX+ rituximab +transplant - Transplant	0.76904446	1				
HD-MTX+ transplant - Transplant	0.16538519	1				
Rituximab +transplant - Transplant	-0.04289046	1				

Supplemental Table 6: Analysis of B-cell histologies on (A) OS, (B) treatment 1 to progression, (C) symptom onset to diagnosis, and (D) symptom onset to death periods.

6A

Overall Survival						
Types of B-cell lymphoma	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Diffuse large B-cell	250	10	10.1106	7.10632653	5.89140494	34.3262531
Unspecified B-cell	15	5	22.8969667	39.9328875	0	102.752422
Follicular	13	10	25.44769251	2.683281573	20.08112916	30.81425545
IVL	12	9.4	10.2	#REF!	#REF!	#REF!
Burkitt	11	2.8	3.69454545	2.89239268	0	9.47873079
Lymphoplasmacytic	11	18	25.58181818	25.36135193	0	77.30452218
High-grade B-cell	9	4	8.068888889	10.10779485	0	28.302969
CLL/SLL	8	17	38.75	39.44952346	0	111.640169
Mantle cell	8	7.45	8.05	46.722332	0	116.486164
Marginal zone	7	25.4	39.94285714	47.1964872	0	151.2557305
Low-grade B-cell	6	81.7	81.7	61.67359948	0	205.04712
Intermediate & triple-hit B-cell	2	3	3	4.24264087	0	11.48528137
MALT	1	0	0	N/A	N/A	N/A
Acute lymphoblastic leukemia	1	27	27	N/A	N/A	N/A
Plasma cell leukemia	1	38	38	N/A	N/A	N/A
N/A=Not applicable						
Kruskal-Wallis chi-squared = 36.033	df = 14	p value = 0.01032				
		Bonferroni				
Pair	Z score	adjusted p value				
Burkitt vs. Low-grade B-cell	-4.02745334	0.00282824				
Low-grade B-cell vs. Unspecified B-cell	-3.57577872	0.06332314				
High-grade B-cell vs. Low-grade B-cell	-3.2005111	0.0719966				
IVL vs. Low-grade B-cell	-3.09852628	0.101829675				
Diffuse large B-cell vs. Low-grade B-cell	-3.0827462	0.12728326				
Intermediate & triple-hit B-cell vs. Low-grade B-cell	-2.7540749	0.308597859				
Burkitt vs. Marginal zone	-2.72324658	0.3387881				
Burkitt vs. Lymphoplasmacytic	-2.71879582	0.34090228				
Low-grade B-cell vs. Mantle cell	-2.7166837	0.346228788				
Burkitt vs. Diffuse large B-cell	-2.68340222	0.382605739				
Low-grade B-cell vs. MALT	-2.6228112	0.45725872				
Burkitt vs. Follicular	-2.46073783	0.72792129				
Acute lymphoblastic leukemia vs. Burkitt	1.85814389	1				
Acute lymphoblastic leukemia vs. CLL/SLL	0.82212726	1				
Burkitt vs. CLL/SLL	-2.3896336	1				
Acute lymphoblastic leukemia vs. Diffuse large B-cell	1.11222829	1				
CLL/SLL vs. Diffuse large B-cell	0.6570138	1				
Acute lymphoblastic leukemia vs. Follicular	0.89909614	1				
CLL/SLL vs. Follicular	0.12142343	1				
Diffuse large B-cell vs. Follicular	-0.6377273	1				
Acute lymphoblastic leukemia vs. High-grade B-cell	1.49902511	1				
Burkitt vs. High-grade B-cell	-0.8732826	1				
CLL/SLL vs. High-grade B-cell	1.37887934	1				
Diffuse large B-cell vs. High-grade B-cell	1.2929057	1				
Follicular vs. High-grade B-cell	1.41930577	1				
Acute lymphoblastic leukemia vs. Intermediate & triple-hit B-cell	1.7253289	1				
Burkitt vs. Intermediate & triple-hit B-cell	0.2221147	1				
CLL/SLL vs. Intermediate & triple-hit B-cell	1.53853406	1				
Diffuse large B-cell vs. Intermediate & triple-hit B-cell	1.4322263	1				
Follicular vs. Intermediate & triple-hit B-cell	1.5939161	1				
High-grade B-cell vs. Intermediate & triple-hit B-cell	0.7191107	1				
Acute lymphoblastic leukemia vs. IVL	1.35889505	1				
Burkitt vs. IVL	-1.2639281	1				
CLL/SLL vs. IVL	1.1672742	1				
Diffuse large B-cell vs. IVL	1.00435789	1				
Follicular vs. IVL	1.19460386	1				
High-grade B-cell vs. IVL	-0.31120411	1				
Intermediate & triple-hit B-cell vs. IVL	-0.91570704	1				
Acute lymphoblastic leukemia vs. Low-grade B-cell	-0.12819612	1				
CLL/SLL vs. Low-grade B-cell	-1.18248949	1				
Follicular vs. Low-grade B-cell	-2.1703053	1				
Acute lymphoblastic leukemia vs. Lymphoplasmacytic	0.74855115	1				
CLL/SLL vs. Lymphoplasmacytic	-0.2197419	1				
Diffuse large B-cell vs. Lymphoplasmacytic	-1.0795951	1				
Follicular vs. Lymphoplasmacytic	-0.39907458	1				
High-grade B-cell vs. Lymphoplasmacytic	-1.70569358	1				
Intermediate & triple-hit B-cell vs. Lymphoplasmacytic	-1.72862804	1				
IVL vs. Lymphoplasmacytic	-1.50787882	1				
Low-grade B-cell vs. Lymphoplasmacytic	1.8132106	1				
Acute lymphoblastic leukemia vs. MALT	1.90366028	1				
Burkitt vs. MALT	0.72178133	1				
CLL/SLL vs. MALT	1.71264761	1				
Diffuse large B-cell vs. MALT	1.57740862	1				
Follicular vs. MALT	1.69788107	1				
High-grade B-cell vs. MALT	1.0276846	1				
Intermediate & triple-hit B-cell vs. MALT	0.47133026	1				
IVL vs. MALT	1.28338739	1				
Lymphoplasmacytic vs. MALT	1.83172507	1				
Acute lymphoblastic leukemia vs. Mantle cell	1.25277004	1				
Burkitt vs. Mantle cell	-1.31789072	1				
CLL/SLL vs. Mantle cell	0.90057951	1				
Diffuse large B-cell vs. Mantle cell	0.5969685	1				
Follicular vs. Mantle cell	0.88064894	1				
High-grade B-cell vs. Mantle cell	-0.45219057	1				
Intermediate & triple-hit B-cell vs. Mantle cell	-0.96900849	1				
IVL vs. Mantle cell	-0.18074199	1				
Lymphoplasmacytic vs. Mantle cell	1.17707475	1				
MALT vs. Mantle cell	-1.38311096	1				
Acute lymphoblastic leukemia vs. Marginal zone	0.5841292	1				
CLL/SLL vs. Marginal zone	-0.4079999	1				
Diffuse large B-cell vs. Marginal zone	-1.27861452	1				
Follicular vs. Marginal zone	-0.65821463	1				
High-grade B-cell vs. Marginal zone	-1.83356132	1				
Intermediate & triple-hit B-cell vs. Marginal zone	-1.85359555	1				
IVL vs. Marginal zone	-1.6543491	1				
Low-grade B-cell vs. Marginal zone	1.37119631	1				
Lymphoplasmacytic vs. Marginal zone	-0.32549705	1				
MALT vs. Marginal zone	-1.6968224	1				
Mantle cell vs. Marginal zone	-1.3603428	1				
Acute lymphoblastic leukemia vs. Plasma cell leukemia	-0.07880316	1				
Burkitt vs. Plasma cell leukemia	-1.98529595	1				
CLL/SLL vs. Plasma cell leukemia	-0.62334784	1				
Diffuse large B-cell vs. Plasma cell leukemia	-1.2240494	1				
Follicular vs. Plasma cell leukemia	-1.00953171	1				
High-grade B-cell vs. Plasma cell leukemia	-1.57479461	1				
Intermediate & triple-hit B-cell vs. Plasma cell leukemia	-1.81408503	1				
IVL vs. Plasma cell leukemia	-1.4630423	1				
Low-grade B-cell vs. Plasma cell leukemia	0.02691536	1				
Lymphoplasmacytic vs. Plasma cell leukemia	-0.85529581	1				
MALT vs. Plasma cell leukemia	-1.98446644	1				
Mantle cell vs. Plasma cell leukemia	-1.25788489	1				
Marginal zone vs. Plasma cell leukemia	-0.68841963	1				
Acute lymphoblastic leukemia vs. Unspecified B-cell	1.35425115	1				
Burkitt vs. Unspecified B-cell	-1.83739395	1				
CLL/SLL vs. Unspecified B-cell	1.31632843	1				
Diffuse large B-cell vs. Unspecified B-cell	2.1556231	1				
Follicular vs. Unspecified B-cell	1.45746185	1				
High-grade B-cell vs. Unspecified B-cell	-0.54287272	1				
Intermediate & triple-hit B-cell vs. Unspecified B-cell	-1.03165966	1				
IVL vs. Unspecified B-cell	-0.16757539	1				
Lymphoplasmacytic vs. Unspecified B-cell	1.8301323	1				
MALT vs. Unspecified B-cell	-1.32870119	1				
Mantle cell vs. Unspecified B-cell	0.08625191	1				
Marginal zone vs. Unspecified B-cell	1.8883171	1				
Plasma cell leukemia vs. Unspecified B-cell	1.48524347	1				

6B

Time from Treatment 1 to Progression						
Types of B-cell lymphoma	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Unspecified B-cell	62	16.5	19.16807018	16.83790912	0	52.84388841
High-grade B-cell	6	11	11	0	11	11
B acute lymphoblastic leukemia	6	9.4	9.4	0	9.4	9.4
Mantle cell	3	12	14.6	5.392587505	3.81482499	25.38517501
Burkitt	3	11	8.333333333	5.507570547	0	19.34847443
MALT	2	14	14	18.38477631	0	50.76955262
Diffuse large B-cell	2	28.4	28.4	10.74802307	6.903953852	49.89604615
CLL/SLL	2	10.2	10.2	1.13137085	7.9372583	12.4627417
Marginal zone	2	2.48	2.48	2.099036072	0	6.666072145
IVL	1	7	7	N/A	N/A	N/A
Follicular	1	1	1	N/A	N/A	N/A
Lymphoplasmacytic	0	N/A	N/A	N/A	N/A	N/A
Low-grade B-cell	0	N/A	N/A	N/A	N/A	N/A
Intermediate & triple-hit B-cell	0	N/A	N/A	N/A	N/A	N/A
Plasma cell leukemia	0	N/A	N/A	N/A	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-squared = 9.9899		df = 10	p value = 0.4414			
Pair	Z score	Bonferroni adjusted p value				
Diffuse large B-cell - Marginal zone	2.1866359	0.7911507				
B acute lymphoblastic leukemia - Burkitt	0.09162578	1				
B acute lymphoblastic leukemia - CLL/SLL	-0.19044061	1				
Burkitt - CLL/SLL	-0.24130829	1				
B acute lymphoblastic leukemia - Diffuse large B-cell	-1.38069443	1				
Burkitt - Diffuse large B-cell	-1.30590367	1				
CLL/SLL - Diffuse large B-cell	-0.97188818	1				
B acute lymphoblastic leukemia - Follicular	1.20566141	1				
Burkitt - Follicular	1.07168887	1				
CLL/SLL - Follicular	1.19025382	1				
Diffuse large B-cell - Follicular	1.98875637	1				
B acute lymphoblastic leukemia - High-grade B-cell	-0.53864739	1				
Burkitt - High-grade B-cell	-0.53142954	1				
CLL/SLL - High-grade B-cell	-0.19044061	1				
Diffuse large B-cell - High-grade B-cell	0.99981321	1				
Follicular - High-grade B-cell	-1.49358055	1				
B acute lymphoblastic leukemia - IVL	0.14395957	1				
Burkitt - IVL	0.07855274	1				
CLL/SLL - IVL	0.25392082	1				
Diffuse large B-cell - IVL	1.04742336	1				
Follicular - IVL	-0.81088817	1				
High-grade B-cell - IVL	0.43187871	1				
B acute lymphoblastic leukemia - MALT	0.22614823	1				
Burkitt - MALT	0.1313001	1				
CLL/SLL - MALT	0.34014336	1				
Diffuse large B-cell - MALT	1.31198154	1				
Follicular - MALT	-0.91252793	1				
High-grade B-cell - MALT	0.60702945	1				
IVL - MALT	0.02380508	1				
B acute lymphoblastic leukemia - Mantle cell	-0.76965657	1				
Burkitt - Mantle cell	-0.7458924	1				
CLL/SLL - Mantle cell	-0.42588815	1				
Diffuse large B-cell - Mantle cell	0.63875723	1				
Follicular - Mantle cell	-1.59910944	1				
High-grade B-cell - Mantle cell	-0.32985282	1				
IVL - Mantle cell	-0.60597832	1				
MALT - Mantle cell	-0.79844654	1				
B acute lymphoblastic leukemia - Marginal zone	1.29737667	1				
Burkitt - Marginal zone	1.08943594	1				
CLL/SLL - Marginal zone	1.21479772	1				
Follicular - Marginal zone	-0.19837564	1				
High-grade B-cell - Marginal zone	1.67825789	1				
IVL - Marginal zone	0.73795737	1				
MALT - Marginal zone	0.87465436	1				
Mantle cell - Marginal zone	1.75658238	1				
B acute lymphoblastic leukemia - Unspecified B-cell	-0.91728984	1				
Burkitt - Unspecified B-cell	-0.77301919	1				
CLL/SLL - Unspecified B-cell	-0.32945801	1				
Diffuse large B-cell - Unspecified B-cell	1.02328348	1				
Follicular - Unspecified B-cell	-1.6809451	1				
High-grade B-cell - Unspecified B-cell	-0.18991053	1				
IVL - Unspecified B-cell	-0.5433138	1				
MALT - Unspecified B-cell	-0.80291753	1				
Mantle cell - Unspecified B-cell	0.25720168	1				
Marginal zone - Unspecified B-cell	-2.02038487	1				
Lymphoplasmacytic - MALT	1.00783217	1				
B acute lymphoblastic leukemia - Mantle cell	-0.40154821	1				

Time from Symptom Onset to Diagnosis						
	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Types of B-cell lymphoma						
Unspecified B-cell	76	3	9.72484205	18.9004251	0	42.53769281
Diffuse large B-cell	7	3	5.214285714	5.804272438	0	16.81683059
Lymphoplasmacytic	3	36	32	30.18623774	0	92.3887548
Follicular	2	1.75	1.75	1.76776953	0	5.26533606
Burkitt	2	25	25	2.12323844	0	6.74264087
Mantle cell	2	7	7	1.414213562	4.171572875	9.828427125
Marginal zone	1	5	5	N/A	N/A	N/A
CLL/SLL	1	1	1	N/A	N/A	N/A
IVL	0	N/A	N/A	N/A	N/A	N/A
Low-grade B-cell	0	N/A	N/A	N/A	N/A	N/A
High-grade B-cell	0	N/A	N/A	N/A	N/A	N/A
MALT	0	N/A	N/A	N/A	N/A	N/A
Intermediate & triple-hit B-cell	0	N/A	N/A	N/A	N/A	N/A
Acute lymphoblastic leukemia	0	N/A	N/A	N/A	N/A	N/A
Plasma cell leukemia	0	N/A	N/A	N/A	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-squared = 4.9476		df = 7	p value = 0.6664			
Pair						
	Z score	Bonferroni		adjusted p value		
Burkitt vs. CLL/SLL	0.6238542	1				
Burkitt vs. Diffuse large B-cell	-0.5851668	1				
CLL/SLL vs. Diffuse large B-cell	-1.13771138	1				
Burkitt vs. Follicular	0.39538188	1				
CLL/SLL vs. Follicular	-0.30038233	1				
Diffuse large B-cell vs. Follicular	1.03525997	1				
Burkitt vs. Lymphoplasmacytic	-0.80861845	1				
CLL/SLL vs. Lymphoplasmacytic	-1.38015485	1				
Diffuse large B-cell vs. Lymphoplasmacytic	-0.54690807	1				
Follicular vs. Lymphoplasmacytic	-1.3429052	1				
Burkitt vs. Mantle cell	-1.14927813	1				
CLL/SLL vs. Mantle cell	-1.56146708	1				
Diffuse large B-cell vs. Mantle cell	-0.29323389	1				
Follicular vs. Mantle cell	-1.5466268	1				
Lymphoplasmacytic vs. Mantle cell	-0.34015485	1				
Burkitt vs. Marginal zone	-0.74316828	1				
CLL/SLL vs. Marginal zone	-1.18328839	1				
Diffuse large B-cell vs. Marginal zone	-0.42756324	1				
Follicular vs. Marginal zone	-1.09600257	1				
Lymphoplasmacytic vs. Marginal zone	-0.25900775	1				
Mantle cell vs. Marginal zone	0.19538739	1				
Burkitt vs. Unspecified B-cell	-0.46463315	1				
CLL/SLL vs. Unspecified B-cell	-1.10300019	1				
Diffuse large B-cell vs. Unspecified B-cell	0.2682357	1				
Follicular vs. Unspecified B-cell	-1.02659021	1				
Lymphoplasmacytic vs. Unspecified B-cell	0.82112294	1				
Mantle cell vs. Unspecified B-cell	1.11586875	1				
Marginal zone vs. Unspecified B-cell	0.55635726	1				
Follicular vs. IVL	0	1				
High-grade B-cell vs. IVL	0.56287083	1				
Intermediate & triple-hit B-cell vs. IVL	0	1				
Acute lymphoblastic leukemia vs. Low-grade B-cell	0	1				
Burkitt vs. Low-grade B-cell	1.05262469	1				
CLL/SLL vs. Low-grade B-cell	1.36025328	1				
Diffuse large B-cell vs. Low-grade B-cell	1.83081683	1				
Follicular vs. Low-grade B-cell	0	1				
High-grade B-cell vs. Low-grade B-cell	0.51847827	1				
Intermediate & triple-hit B-cell vs. Low-grade B-cell	0	1				
IVL vs. Low-grade B-cell	0	1				
Acute lymphoblastic leukemia vs. Lymphoplasmacytic	-0.18907285	1				
Burkitt vs. Lymphoplasmacytic	-0.00047149	1				
CLL/SLL vs. Lymphoplasmacytic	0.97383709	1				
Diffuse large B-cell vs. Lymphoplasmacytic	1.26552607	1				
Follicular vs. Lymphoplasmacytic	-0.50005575	1				
High-grade B-cell vs. Lymphoplasmacytic	0.07096973	1				
Intermediate & triple-hit B-cell vs. Lymphoplasmacytic	-0.30723851	1				
IVL vs. Lymphoplasmacytic	-0.5426977	1				
Low-grade B-cell vs. Lymphoplasmacytic	-0.46569204	1				
Acute lymphoblastic leukemia vs. MALT	0	1				
Burkitt vs. MALT	0.80821407	1				
CLL/SLL vs. MALT	1.08688945	1				
Diffuse large B-cell vs. MALT	1.19350626	1				
Follicular vs. MALT	0	1				
High-grade B-cell vs. MALT	0.40513111	1				
Intermediate & triple-hit B-cell vs. MALT	0	1				
IVL vs. MALT	0	1				
Low-grade B-cell vs. MALT	0	1				
Lymphoplasmacytic vs. MALT	0.36989526	1				
Acute lymphoblastic leukemia vs. Mantle cell	-0.37225118	1				
Burkitt vs. Mantle cell	0.09487182	1				
CLL/SLL vs. Mantle cell	0.4545166	1				
Diffuse large B-cell vs. Mantle cell	0.51121328	1				
Follicular vs. Mantle cell	-0.96785307	1				
High-grade B-cell vs. Mantle cell	-0.38641306	1				
Intermediate & triple-hit B-cell vs. Mantle cell	-0.60028999	1				
IVL vs. Mantle cell	-1.03964097	1				
Low-grade B-cell vs. Mantle cell	-0.94803802	1				
Lymphoplasmacytic vs. Mantle cell	-0.465262014	1				
MALT vs. Mantle cell	-0.72291427	1				
Acute lymphoblastic leukemia vs. Marginal zone	-0.36027886	1				
Burkitt vs. Marginal zone	0.04770516	1				
CLL/SLL vs. Marginal zone	0.44164403	1				
Diffuse large B-cell vs. Marginal zone	0.4471634	1				
Follicular vs. Marginal zone	-1.01471883	1				
High-grade B-cell vs. Marginal zone	-0.40522268	1				
Intermediate & triple-hit B-cell vs. Marginal zone	-0.6289052	1				
IVL vs. Marginal zone	-1.03964094	1				
Low-grade B-cell vs. Marginal zone	-0.99501466	1				
Lymphoplasmacytic vs. Marginal zone	-0.5428546	1				
MALT vs. Marginal zone	-0.7631414	1				
Mantle cell vs. Marginal zone	-0.04895864	1				
Acute lymphoblastic leukemia vs. Plasma cell leukemia	0	1				
Burkitt vs. Plasma cell leukemia	0.40689334	1				
CLL/SLL vs. Plasma cell leukemia	0.96790638	1				
Diffuse large B-cell vs. Plasma cell leukemia	0.5368128	1				
Follicular vs. Plasma cell leukemia	0	1				
High-grade B-cell vs. Plasma cell leukemia	0.21166787	1				
Intermediate & triple-hit B-cell vs. Plasma cell leukemia	0	1				
IVL vs. Plasma cell leukemia	0	1				
Low-grade B-cell vs. Plasma cell leukemia	0	1				
Lymphoplasmacytic vs. Plasma cell leukemia	0.18907285	1				
MALT vs. Plasma cell leukemia	0	1				
Mantle cell vs. Plasma cell leukemia	0.37225118	1				
Marginal zone vs. Plasma cell leukemia	0.39027686	1				
Acute lymphoblastic leukemia vs. Unspecified B-cell	-0.97138878	1				
Burkitt vs. Unspecified B-cell	-1.57324276	1				
CLL/SLL vs. Unspecified B-cell	-1.0210141	1				
Diffuse large B-cell vs. Unspecified B-cell	-1.9040218	1				
High-grade B-cell vs. Unspecified B-cell	-1.96753831	1				
Intermediate & triple-hit B-cell vs. Unspecified B-cell	-1.6033717	1				
Lymphoplasmacytic vs. Unspecified B-cell	-2.2610577	1				
MALT vs. Unspecified B-cell	-1.97416818	1				
Mantle cell vs. Unspecified B-cell	-1.65326939	1				
Marginal zone vs. Unspecified B-cell	-1.58795011	1				
Plasma cell leukemia vs. Unspecified B-cell	-0.97138878	1				

6D

Time from Symptom Onset to Death						
Types of B-cell lymphoma	N	Median (no rths)	Mean (no rths)	Standard deviation	Lower bound	Upper bound
Diffuse large B-cell	263	10	21.93016031	32.8752773	0	87.68074421
Unspecified B-cell	17	4	23.34117647	39.32246599	0	100.48355678
Follicular	13	10	25.44769251	38.51564441	0	102.4786821
Burkitt	12	3.14	4.553333333	4.011821924	0	12.57697718
IVL	12	9.4	10.2	11.0374668	0	32.36746676
Lymphoplasmacytic	11	18	26.03636364	26.55406355	0	83.14440074
CLL/SLL	9	10	45.11111111	33.30494333	0	102.9009423
High-grade B-cell	9	5	8.2	9.00002877	0	26.22003575
Mantle cell	8	8.95	23.4875	45.54038104	0	116.5736621
Marginal zone	8	18.7	32.95	45.0391768	0	126.12836
Low-grade B-cell	6	81.7	81.7	61.67355966	0	205.04712
Intermediate & triple-hit B-cell	2	3	3	4.24240087	0	11.48528137
MALT	1	0	0	N/A	N/A	N/A
Acute lymphoblastic leukemia	1	7	7	N/A	N/A	N/A
Plasma cell leukemia	1	38	38	N/A	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-squared = 35.834		df= 14	p value = 0.01105			
Bonferroni adjusted p-value						
Pair	Z score		Adjusted p-value			
Burkitt vs. low grade B cell	-4.2283388	0.00000000				
low grade B cell vs. Unspecified B cell	3.55434003	0.000000316				
High-grade B-cell vs. low grade B-cell	-3.37032746	0.000416427				
IVL vs. low grade B-cell	-3.20486973	0.001600273				
Diffuse large B-cell vs. low grade B-cell	-2.9740092	0.003804528				
Burkitt vs. Diffuse large B-cell	-2.96370145	0.003871183				
Intermediate & triple-hit B-cell vs. low grade B-cell	-2.8521489	0.0022760732				
Burkitt vs. lymphoplasmacytic	-2.8193229	0.006832046				
low grade B-cell vs. Mantle cell	2.77740459	0.007620245				
low grade B-cell vs. MALT	2.6678283	0.000802682				
Burkitt vs. Marginal zone	-2.53046517	0.006034818				
Burkitt vs. Follicular	-2.42393746	0.006045544				
Acute lymphoblastic leukemia vs. Burkitt	1.81742577	1				
Acute lymphoblastic leukemia vs. CLL/SLL	0.90422457	1				
Burkitt vs. CLL/SLL	-2.13561028	1				
Acute lymphoblastic leukemia vs. Diffuse large B-cell	1.03500854	1				
CLL/SLL vs. Diffuse large B-cell	0.18772511	1				
Acute lymphoblastic leukemia vs. Follicular	0.88777659	1				
CLL/SLL vs. Follicular	-0.09603796	1				
Diffuse large B-cell vs. Follicular	-0.33677162	1				
Acute lymphoblastic leukemia vs. High-grade B-cell	1.48430514	1				
Burkitt vs. High-grade B-cell	-0.747170	1				
CLL/SLL vs. High-grade B-cell	1.30475633	1				
Diffuse large B-cell vs. High-grade B-cell	1.61669402	1				
Follicular vs. High-grade B-cell	1.48450763	1				
Acute lymphoblastic leukemia vs. Intermediate & triple-hit B-cell	1.73066015	1				
Burkitt vs. Intermediate & triple-hit B-cell	0.2685222	1				
CLL/SLL vs. Intermediate & triple-hit B-cell	1.48690775	1				
Diffuse large B-cell vs. Intermediate & triple-hit B-cell	1.93367424	1				
Follicular vs. Intermediate & triple-hit B-cell	1.5781357	1				
High-grade B-cell vs. Intermediate & triple-hit B-cell	0.70960008	1				
Acute lymphoblastic leukemia vs. IVL	1.37680611	1				
Burkitt vs. IVL	-1.11573283	1				
CLL/SLL vs. IVL	1.30259311	1				
Diffuse large B-cell vs. IVL	1.4203257	1				
Follicular vs. IVL	1.2814268	1				
High-grade B-cell vs. IVL	-0.20225007	1				
Intermediate & triple-hit B-cell vs. IVL	-0.86533685	1				
Acute lymphoblastic leukemia vs. low grade B-cell	-0.18962638	1				
CLL/SLL vs. low grade B-cell	-2.2031792	1				
Follicular vs. low grade B-cell	-2.24979722	1				
Acute lymphoblastic leukemia vs. lymphoplasmacytic	0.88768312	1				
CLL/SLL vs. lymphoplasmacytic	-0.51483484	1				
Diffuse large B-cell vs. lymphoplasmacytic	-0.69970332	1				
Follicular vs. lymphoplasmacytic	-0.40489048	1				
High-grade B-cell vs. lymphoplasmacytic	-1.88327482	1				
Intermediate & triple-hit B-cell vs. lymphoplasmacytic	-1.82060699	1				
IVL vs. lymphoplasmacytic	-1.71911487	1				
low grade B-cell vs. lymphoplasmacytic	1.63218729	1				
Acute lymphoblastic leukemia vs. MALT	1.38817505	1				
Burkitt vs. MALT	0.74859213	1				
CLL/SLL vs. MALT	1.65203109	1				
Diffuse large B-cell vs. MALT	1.68017207	1				
Follicular vs. MALT	1.68536947	1				
High-grade B-cell vs. MALT	1.08454852	1				
Intermediate & triple-hit B-cell vs. MALT	0.1482739	1				
IVL vs. MALT	1.18571859	1				
lymphoplasmacytic vs. MALT	1.38644249	1				
Acute lymphoblastic leukemia vs. Mantle cell	1.2148996	1				
Burkitt vs. Mantle cell	-1.3287986	1				
CLL/SLL vs. Mantle cell	0.69714548	1				
Diffuse large B-cell vs. Mantle cell	0.75712802	1				
Follicular vs. Mantle cell	0.81736125	1				
High-grade B-cell vs. Mantle cell	-0.59895428	1				
Intermediate & triple-hit B-cell vs. Mantle cell	-1.05148342	1				
IVL vs. Mantle cell	-0.3203811	1				
lymphoplasmacytic vs. Mantle cell	1.2203188	1				
MALT vs. Mantle cell	-1.30256714	1				
Acute lymphoblastic leukemia vs. Marginal zone	0.69452004	1				
CLL/SLL vs. Marginal zone	-0.4384983	1				
Diffuse large B-cell vs. Marginal zone	-0.78109204	1				
Follicular vs. Marginal zone	-0.41080283	1				
High-grade B-cell vs. Marginal zone	-1.70407676	1				
Intermediate & triple-hit B-cell vs. Marginal zone	-1.74878003	1				
IVL vs. Marginal zone	-1.5325293	1				
low grade B-cell vs. Marginal zone	1.75536303	1				
lymphoplasmacytic vs. Marginal zone	0.0388552	1				
MALT vs. Marginal zone	-1.8204969	1				
Mantle cell vs. Marginal zone	-1.10410387	1				
Acute lymphoblastic leukemia vs. Plasma cell leukemia	-0.13135131	1				
Burkitt vs. Plasma cell leukemia	-1.96990385	1				
CLL/SLL vs. Plasma cell leukemia	-1.0742785	1				
Diffuse large B-cell vs. Plasma cell leukemia	-1.20048572	1				
Follicular vs. Plasma cell leukemia	-1.0873163	1				
High-grade B-cell vs. Plasma cell leukemia	-1.66033281	1				
Intermediate & triple-hit B-cell vs. Plasma cell leukemia	-1.88262558	1				
IVL vs. Plasma cell leukemia	-1.58827739	1				
low grade B-cell vs. Plasma cell leukemia	0.0264014	1				
lymphoplasmacytic vs. Plasma cell leukemia	-0.86580363	1				
MALT vs. Plasma cell leukemia	-2.00953036	1				
Mantle cell vs. Plasma cell leukemia	-1.36033488	1				
Marginal zone vs. Plasma cell leukemia	-0.88995512	1				
Acute lymphoblastic leukemia vs. Unspecified B-cell	1.43490911	1				
Burkitt vs. Unspecified B-cell	-1.1000469	1				
CLL/SLL vs. Unspecified B-cell	1.27733876	1				
Diffuse large B-cell vs. Unspecified B-cell	1.83628406	1				
Follicular vs. Unspecified B-cell	1.50594823	1				
High-grade B-cell vs. Unspecified B-cell	-0.24070168	1				
Intermediate & triple-hit B-cell vs. Unspecified B-cell	-0.88076828	1				
IVL vs. Unspecified B-cell	0.10704856	1				
lymphoplasmacytic vs. Unspecified B-cell	1.65879212	1				
MALT vs. Unspecified B-cell	-1.16013928	1				
Mantle cell vs. Unspecified B-cell	0.43803886	1				
Marginal zone vs. Unspecified B-cell	1.72560417	1				
Plasma cell leukemia vs. Unspecified B-cell	1.61548422	1				

Supplemental Table 7: Analysis of T-cell histologies on (A) OS, (B) treatment 1 to progression, (C) symptom onset to diagnosis, and (D) symptom onset to death periods.

7A

Overall Survival						
Types of T-cell lymphoma	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
T lymphoblastic lymphoma/leukemia	3	10	11.55333333	4.356060263	1.641212807	21.46545386
Peripheral T-cell	7	10	33.96142857	47.265002	0	128.4914326
Cutaneous T-cell	4	3	5.625	5.618051264	0	16.86110253
Adult T-cell leukemia/lymphoma	2	45.5	45.5	64.34671709	0	174.1934342
Extranodal NK/T-cell* (lymphoma, nasal type)	7	1	5.28	5.29683868	0	15.87367736
ALCL	2	11.65	11.65	10.81873975	0	33.2874675
Unspecified T-cell	15	10	16.40666667	15.69160224	0	47.78987115
Enteropathy-associated T-cell	1	1.3	1.3	N/A	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-squared = 8.5973		df = 7	p value = 0.2829			
Pair	Z score	Bonferroni adjusted p value				
Extranodal NK/T-cell* (lymphoma, nasal type) vs. Peripheral T-cell	-2.29291654	0.3059393				
Extranodal NK/T-cell* (lymphoma, nasal type) vs. Unspecified T-cell	-1.97228658	0.6800766				
Adult T-cell leukemia/lymphoma vs. ALCL	-0.18924944	1				
Adult T-cell leukemia/lymphoma vs. Cutaneous T-cell	0.60701787	1				
ALCL vs. Cutaneous T-cell	0.82554431	1				
Adult T-cell leukemia/lymphoma vs. Enteropathy-associated T-cell	0.87562197	1				
ALCL vs. Enteropathy-associated T-cell	1.03014349	1				
Cutaneous T-cell vs. Enteropathy-associated T-cell	0.48900178	1				
Adult T-cell leukemia/lymphoma vs. Extranodal NK/T-cell* (lymphoma, nasal type)	0.81301126	1				
ALCL vs. Extranodal NK/T-cell* (lymphoma, nasal type)	1.04904678	1				
Cutaneous T-cell vs. Extranodal NK/T-cell* (lymphoma, nasal type)	0.20129177	1				
Enteropathy-associated T-cell vs. Extranodal NK/T-cell* (lymphoma, nasal type)	-0.39339254	1				
Adult T-cell leukemia/lymphoma vs. Peripheral T-cell	-0.71559977	1				
ALCL vs. Peripheral T-cell	-0.47956424	1				
Cutaneous T-cell vs. Peripheral T-cell	-1.75411402	1				
Enteropathy-associated T-cell vs. Peripheral T-cell	-1.53985082	1				
Adult T-cell leukemia/lymphoma vs. T lymphoblastic lymphoma/leukemia	-0.16124236	1				
ALCL vs. T lymphoblastic lymphoma/leukemia	0.04606342	1				
Cutaneous T-cell vs. T lymphoblastic lymphoma/leukemia	-0.88101577	1				
Enteropathy-associated T-cell vs. T lymphoblastic lymphoma/leukemia	-1.0562111	1				
Extranodal NK/T-cell* (lymphoma, nasal type) vs. T lymphoblastic lymphoma/leukemia	-1.15793811	1				
Peripheral T-cell vs. T lymphoblastic lymphoma/leukemia	0.61814741	1				
Adult T-cell leukemia/lymphoma vs. Unspecified T-cell	-0.333342	1				
ALCL vs. Unspecified T-cell	-0.08193882	1				
Cutaneous T-cell vs. Unspecified T-cell	-1.38009643	1				
Enteropathy-associated T-cell vs. Unspecified T-cell	-1.28132257	1				
Peripheral T-cell vs. Unspecified T-cell	0.70526306	1				
T lymphoblastic lymphoma/leukemia vs. Unspecified T-cell	-0.16402218	1				

7B

Time from Treatment 1 to Progression						
Types of T-cell lymphoma	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Unspecified T-cell	3	9.4	8.133333333	5.608327142	0	19.34998762
Peripheral T-cell	1	11	11	N/A	N/A	N/A
Extranodal NK/T-cell* (lymphoma, nasal type)	1	8	8	N/A	N/A	N/A
T lymphoblastic lymphoma/leukemia	0	N/A	N/A	N/A	N/A	N/A
Cutaneous T-cell	0	N/A	N/A	N/A	N/A	N/A
Adult T-cell leukemia/lymphoma	0	N/A	N/A	N/A	N/A	N/A
ALCL	0	N/A	N/A	N/A	N/A	N/A
Enteropathy-associated T-cell	0	N/A	N/A	N/A	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-squared = 0.8	df = 2	p value = 0.6703				
Pair	Z score	Bonferroni adjusted p value				
Extranodal NK/T-cell* (lymphoma, nasal type) vs. Peripheral T-cell	-0.8944272	0.5566401				
Extranodal NK/T-cell* (lymphoma, nasal type) vs. Unspecified T-cell	-0.5477226	0.8758236				
Peripheral T-cell vs. Unspecified T-cell	0.5477226	0.8758236				

Time from Symptom Onset to Diagnosis						
Types of T-cell lymphoma	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Extranodal NK/T-cell* (lymphoma, nasal type)	5	2	2.466666667	2.216228027	0	6.89912272
Peripheral T-cell	2	6.125	6.125	8.308504679	0	22.74200936
Unspecified T-cell	2	4	4	2.828427125	0	9.656854249
T lymphoblastic lymphoma/leukemia	1	0.9	0.9	N/A	N/A	N/A
Cutaneous T-cell	1	2	2	N/A	N/A	N/A
Adult T-cell leukemia/lymphoma	1	6	6	N/A	N/A	N/A
Enteropathy-associated T-cell	1	0	0	N/A	N/A	N/A
ALCL	0	N/A	N/A	N/A	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-squared = 4.6854		df = 6	p value = 0.5847			
Pair	Z score	Bonferroni adjusted p value				
Adult T-cell leukemia/lymphoma vs. Enteropathy-associated T-cell	1.8359702	0.6968017				
Enteropathy-associated T-cell vs. Unspecified T-cell	-1.6959966	0.9438085				
Adult T-cell leukemia/lymphoma vs. Cutaneous T-cell	0.7343881	1				
Cutaneous T-cell vs. Enteropathy-associated T-cell	1.1015821	1				
Adult T-cell leukemia/lymphoma vs. Extranodal NK/T-cell* (lymphoma, nasal type)	0.9480909	1				
Cutaneous T-cell vs. Extranodal NK/T-cell* (lymphoma, nasal type)	0	1				
Enteropathy-associated T-cell vs. Extranodal NK/T-cell* (lymphoma, nasal type)	-1.4221364	1				
Adult T-cell leukemia/lymphoma vs. Peripheral T-cell	0.7419985	1				
Cutaneous T-cell vs. Peripheral T-cell	-0.1059998	1				
Enteropathy-associated T-cell vs. Peripheral T-cell	-1.3779972	1				
Extranodal NK/T-cell* (lymphoma, nasal type) vs. Peripheral T-cell	-0.1551678	1				
Adult T-cell leukemia/lymphoma vs. T lymphoblastic lymphoma/leukemia	1.2851791	1				
Cutaneous T-cell vs. T lymphoblastic lymphoma/leukemia	0.5507911	1				
Enteropathy-associated T-cell vs. T lymphoblastic lymphoma/leukemia	-0.5507911	1				
Extranodal NK/T-cell* (lymphoma, nasal type) vs. T lymphoblastic lymphoma/leukemia	0.7110682	1				
Peripheral T-cell vs. T lymphoblastic lymphoma/leukemia	0.7419985	1				
Adult T-cell leukemia/lymphoma vs. Unspecified T-cell	0.4239992	1				
Cutaneous T-cell vs. Unspecified T-cell	-0.4239992	1				
Extranodal NK/T-cell* (lymphoma, nasal type) vs. Unspecified T-cell	-0.6206712	1				
Peripheral T-cell vs. Unspecified T-cell	-0.3894681	1				
T lymphoblastic lymphoma/leukemia vs. Unspecified T-cell	-1.0599979	1				

Time from Symptom Onset to Death						
Types of T-cell lymphoma	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
T lymphoblastic lymphoma/leukemia	3	10	11.85333333	5.461184243	0.930964848	22.77570182
Peripheral T-cell	7	19	35.71142857	47.02980878	0	129.7710461
Cutaneous T-cell	4	4.25	6.125	5.390964663	0	16.90692933
Adult T-cell leukemia/lymphoma	2	48.5	48.5	60.1040764	0	168.7081528
Extranodal NK/T-cell* (lymphoma, nasal type)	7	5.996666667	7.041904762	6.530582714	0	20.10907019
ALCL	2	11.65	11.65	10.81873375	0	33.2874675
Unspecified T-cell	18	10	14.83888889	14.78946918	0	44.41782725
Enteropathy-associated T-cell	1	1.3	1.3	N/A	N/A	N/A
N/A = Not applicable						
Kruskal-Wallis chi-squared = 8.489	df = 7	p value = 0.2915				
Pair	Z score	Bonferroni adjusted p value				
Extranodal NK/T-cell* (lymphoma, nasal type) - Peripheral T-cell	-2.08303345	0.5214744				
Cutaneous T-cell - Peripheral T-cell	-1.84559896	0.9093064				
Enteropathy-associated T-cell - Peripheral T-cell	-1.80564457	0.9396343				
Adult T-cell leukemia/lymphoma - ALCL	0.43082398	1				
Adult T-cell leukemia/lymphoma - Cutaneous T-cell	1.2776003	1				
ALCL - Cutaneous T-cell	0.78012762	1				
Adult T-cell leukemia/lymphoma - Enteropathy-associated T-cell	1.53498026	1				
ALCL - Enteropathy-associated T-cell	1.18321365	1				
Cutaneous T-cell - Enteropathy-associated T-cell	0.69186168	1				
Adult T-cell leukemia/lymphoma - Extranodal NK/T-cell* (lymphoma, nasal type)	1.32588394	1				
ALCL - Extranodal NK/T-cell* (lymphoma, nasal type)	0.78855203	1				
Cutaneous T-cell - Extranodal NK/T-cell* (lymphoma, nasal type)	-0.06918207	1				
Enteropathy-associated T-cell - Extranodal NK/T-cell* (lymphoma, nasal type)	-0.76412785	1				
Adult T-cell leukemia/lymphoma - Peripheral T-cell	-0.06280503	1				
ALCL - Peripheral T-cell	-0.60013694	1				
Adult T-cell leukemia/lymphoma - T lymphoblastic lymphoma/leukemia	0.38613602	1				
ALCL - T lymphoblastic lymphoma/leukemia	-0.085808	1				
Cutaneous T-cell - T lymphoblastic lymphoma/leukemia	-0.98714175	1				
Enteropathy-associated T-cell - T lymphoblastic lymphoma/leukemia	-1.32282509	1				
Extranodal NK/T-cell* (lymphoma, nasal type) - T lymphoblastic lymphoma/leukemia	-1.02972798	1				
Peripheral T-cell - T lymphoblastic lymphoma/leukemia	0.58378279	1				
Adult T-cell leukemia/lymphoma - Unspecified T-cell	0.52838362	1				
ALCL - Unspecified T-cell	-0.04962721	1				
Cutaneous T-cell - Unspecified T-cell	-1.2891424	1				
Enteropathy-associated T-cell - Unspecified T-cell	-1.446488	1				
Extranodal NK/T-cell* (lymphoma, nasal type) - Unspecified T-cell	-1.50243585	1				
Peripheral T-cell - Unspecified T-cell	0.99720429	1				
T lymphoblastic lymphoma/leukemia - Unspecified T-cell	0.0662942	1				

Supplemental Table 8: Analysis of peripheral nerve involvements on (A) OS, (B) treatment 1 to progression, (C) symptom onset to diagnosis, and (D) symptom onset to death periods.

8A

Overall Survival							
Category & Types of Peripheral Nerves	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound	
<i>Cranial nerves</i>	Cranial nerves	106	10	24.7682075	40.88375262	0	91.76750524
	Brachial plexus	99	7	20.3367677	33.9720242	0	74.9440484
<i>Neural plexus</i>	Lumbosacral plexus	114	8.52	24.6679825	40.34197924	0	89.20395848
	Unspecified plexus	114	8.52	24.6679825	40.34197924	0	89.20395848
<i>Spinal nerves</i>	Cervical nerve roots	42	4	10.7380952	20.83334759	0	45.66669518
	Thoracic nerve roots	29	5	10.9420690	19.43490773	0	43.86981546
	Lumbar & sacral nerve roots	57	7.56	16.6591228	21.0904757	0	49.7409514
	Unspecified spinal nerve roots	33	10	17.1715152	31.4654133	0	72.9108266
<i>Peripheral nerves</i>	Distal upper extremity nerves	27	5	9.7814815	18.06786431	0	41.13572862
	Distal lower extremity nerves	114	6.35	21.2475439	36.34646557	0	79.04091314
	Unspecified peripheral nerves	74	10	14.3059459	18.40349921	0	46.80699843
Kruskal-Wallis chi-squared = 49.824	df = 10	p value = 0.00602					
		Bonferroni adjusted					
Pair	Z score	p value					
Cervical nerve roots vs. Unspecified peripheral nerves	-3.72466713	0.00537626					
Distal upper extremities nerves vs. Unspecified peripheral nerves	-3.18487216	0.03982494					
Cervical nerve roots vs. Cranial nerves	-2.75961929	0.15913908					
Thoracic nerve roots vs. Unspecified peripheral nerves	-2.73253128	0.17283688					
Cervical nerve roots vs. Lumbosacral plexus	-2.70501651	0.18782773					
Cervical nerve roots vs. Unspecified plexus	-2.70501651	0.18782773					
Cervical nerve roots vs. Unspecified spinal nerve roots	-2.64839498	0.22241282					
Cervical nerve roots vs. Lumbar & sacral nerve roots	-2.40797836	0.44113112					
Distal upper extremities nerves vs. Unspecified spinal nerve roots	-2.36055961	0.5018031					
Distal lower extremity nerves vs. Unspecified peripheral nerves	-2.32158588	0.55701923					
Cranial nerves vs. Distal upper extremities nerves	2.31779462	0.56266336					
Brachial plexus vs. Cervical nerve roots	2.30035881	0.58926726					
Distal upper extremities nerves vs. Lumbosacral plexus	-2.26480746	0.64675487					
Distal upper extremities nerves vs. Unspecified plexus	-2.26480746	0.64675487					
Brachial plexus vs. Cranial nerves	-0.569152	1					
Brachial plexus vs. Distal lower extremity nerves	0.38836457	1					
Cervical nerve roots vs. Distal lower extremity nerves	-2.06645094	1					
Cranial nerves vs. Distal lower extremity nerves	0.96461306	1					
Brachial plexus vs. Distal upper extremities nerves	1.93494226	1					
Cervical nerve roots vs. Distal upper extremities nerves	-0.01421201	1					
Distal lower extremity nerves vs. Distal upper extremities nerves	1.72637054	1					
Brachial plexus vs. Lumbar & sacral nerve roots	-0.39736229	1					
Cranial nerves vs. Lumbar & sacral nerve roots	0.08207385	1					
Distal lower extremity nerves vs. Lumbar & sacral nerve roots	-0.71922628	1					
Distal upper extremities nerves vs. Lumbar & sacral nerve roots	-2.08097748	1					
Brachial Plexus vs. Lumbosacral plexus	-0.47065279	1					
Cranial nerves vs. Lumbosacral plexus	0.11036353	1					
Distal lower extremity nerves vs. Lumbosacral plexus	-0.87021819	1					
Lumbar & sacral nerve roots vs. Lumbosacral plexus	0.00869611	1					
Brachial plexus vs. Thoracic nerve roots	1.43347477	1					
Cervical nerve roots vs. Thoracic nerve roots	-0.50087593	1					
Cranial nerves vs. Thoracic nerve roots	1.82391454	1					
Distal lower extremity nerves vs. Thoracic nerve roots	1.21200941	1					
Distal upper extremities nerves vs. Thoracic nerve roots	-0.43908295	1					
Lumbar & sacral nerve roots vs. Thoracic nerve roots	1.61663893	1					
Lumbosacral plexus vs. Thoracic nerve roots	1.76621913	1					
Brachial plexus vs. Unspecified Peripheral nerves	-1.92599532	1					
Cranial nerves vs. Unspecified Peripheral nerves	-1.4286572	1					
Lumbar & sacral nerve roots vs. Unspecified Peripheral nerves	-1.30453549	1					
Lumbosacral plexus vs. Unspecified Peripheral nerves	-1.54947426	1					
Brachial plexus vs. Unspecified plexus	-0.47065279	1					
Cranial nerves vs. Unspecified plexus	0.11036353	1					
Distal lower extremity nerves vs. Unspecified plexus	-0.87021819	1					
Lumbar & sacral nerve roots vs. Unspecified plexus	0.00869611	1					
Lumbosacral plexus vs. Unspecified plexus	0	1					
Thoracic nerve roots vs. Unspecified plexus	-1.76621913	1					
Unspecified peripheral nerves vs. Unspecified plexus	1.54947426	1					
Brachial plexus vs. Unspecified spinal nerve roots	-0.95749285	1					
Cranial nerves vs. Unspecified spinal nerve roots	-0.56643685	1					
Distal lower extremity nerves vs. Unspecified spinal nerve roots	-1.22964552	1					
Lumbar & sacral nerve roots vs. Unspecified spinal nerve roots	-0.57783339	1					
Lumbosacral plexus vs. Unspecified spinal nerve roots	-0.64654765	1					
Thoracic nerve roots vs. Unspecified spinal nerve roots	-1.94530545	1					
Unspecified peripheral nerves vs. Unspecified spinal nerve roots	0.4944714	1					
Unspecified plexus vs. Unspecified spinal nerve roots	-0.64654765	1					

Time from Treatment 1 to Progression							
Category & Types of Peripheral Nerves	N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound	
<i>Cranial nerves</i>	Cranial nerves	25	9.4	16.042	14.24669318	0	37.89338637
<i>Neural plexus</i>	Brachial plexus	23	36	22.0326087	15.66051497	4.678870052	67.32102995
	Lumbosacral plexus	36	18.9	19.71388889	14.81415159	0	48.52830318
<i>Spinal nerves</i>	Unspecified plexus	7	6.4	6.4	9.59342E-16	6.4	6.4
	Cervical nerve roots	6	3	3.375	2.200852108	0	7.401704215
	Thoracic nerve roots	3	6	5	1.732050808	2.535898385	9.464101615
	Lumbar & sacral nerve roots	10	6	13.783	23.65665236	0	53.31330473
<i>Peripheral nerves</i>	Unspecified spinal nerve roots	5	11	7.642	4.696894719	1.606210562	20.39378944
	Distal upper extremity nerves	1	8	8	N/A	N/A	N/A
	Distal lower extremity nerves	30	11	16.58	12.20538262	0	35.41036524
Unspecified peripheral nerves	13	9.4	10.41538462	5.468980123	0	20.33796025	
N/A = Not applicable							
Kruskal-Wallis chi-squared = 21.558		df = 10	p value = 0.01572				
Pair	Z score	Bonferroni adjusted p value					
Brachial plexus vs. Cervical nerve roots	3.25377157	0.03131805					
Cervical nerve roots vs. Lumbosacral plexus	-3.22123907	0.03510035					
Cervical nerve roots vs. Distal lower extremity nerves	-3.06746997	0.05936677					
Cervical nerve roots vs. Cranial nerves	-2.64487963	0.22466354					
Cervical nerve roots vs. Unspecified peripheral nerves	-2.19854113	0.76754059					
Brachial plexus vs. Lumbar & sacral nerve roots	2.19076527	0.78289153					
Lumbar & sacral nerve roots vs. Lumbosacral plexus	-2.1224255	0.92955563					
Brachial plexus vs. Cranial nerves	1.0007963	1					
Brachial plexus vs. Distal lower extremity nerves	0.43213429	1					
Cranial nerves vs. Distal lower extremity nerves	-0.62551593	1					
Brachial plexus vs. Distal upper extremities nerves	0.52857918	1					
Cervical nerve roots vs. Distal upper extremities nerves	-0.88104013	1					
Cranial nerves vs. Distal upper extremities nerves	0.24592146	1					
Distal lower extremity nerves vs. Distal upper extremities nerves	0.41334949	1					
Cervical nerve roots vs. Lumbar & sacral nerve roots	-1.28147399	1					
Cranial nerves vs. Lumbar & sacral nerve roots	1.44501055	1					
Distal lower extremity nerves vs. Lumbar & sacral nerve roots	1.94459022	1					
Distal upper extremities nerves vs. Lumbar & sacral nerve roots	0.27639143	1					
Brachial plexus vs. Lumbosacral plexus	0.26652966	1					
Cranial nerves vs. Lumbosacral plexus	-0.83739636	1					
Distal lower extremity nerves vs. Lumbosacral plexus	-0.19667208	1					
Distal upper extremities nerves vs. Lumbosacral plexus	-0.46242227	1					
Brachial plexus vs. Thoracic nerve roots	2.04442288	1					
Cervical nerve roots vs. Thoracic nerve roots	-0.35198134	1					
Cranial nerves vs. Thoracic nerve roots	1.56058857	1					
Distal lower extremity nerves vs. Thoracic nerve roots	1.85445106	1					
Distal upper extremities nerves vs. Thoracic nerve roots	0.6085939	1					
Lumbar & sacral nerve roots vs. Thoracic nerve roots	0.62738229	1					
Lumbosacral plexus vs. Thoracic nerve roots	1.94956792	1					
Brachial plexus vs. Unspecified peripheral nerves	1.17148986	1					
Cranial nerves vs. Unspecified peripheral nerves	0.34315339	1					
Distal lower extremity nerves vs. Unspecified peripheral nerves	0.86351294	1					
Distal upper extremities nerves vs. Unspecified peripheral nerves	-0.12859923	1					
Lumbar & sacral nerve roots vs. Unspecified peripheral nerves	-1.00645059	1					
Lumbosacral plexus vs. Unspecified peripheral nerves	1.03638094	1					
Thoracic nerve roots vs. Unspecified peripheral nerves	-1.30551283	1					
Brachial plexus vs. Unspecified plexus	1.78502785	1					
Cervical nerve roots vs. Unspecified plexus	-1.29602963	1					
Cranial nerves vs. Unspecified plexus	1.12572308	1					
Distal lower extremity nerves vs. Unspecified plexus	1.55037329	1					
Distal upper extremities nerves vs. Unspecified plexus	0.21569512	1					
Lumbar & sacral nerve roots vs. Unspecified plexus	-0.1203193	1					
Lumbosacral plexus vs. Unspecified plexus	1.69310771	1					
Thoracic nerve roots vs. Unspecified plexus	-0.68421894	1					
Unspecified peripheral nerves vs. Unspecified plexus	0.77652708	1					
Brachial plexus vs. Unspecified spinal nerve roots	1.46366125	1					
Cervical nerve roots vs. Unspecified spinal nerve roots	-1.27055284	1					
Cranial nerves vs. Unspecified spinal nerve roots	0.88399188	1					
Distal lower extremity nerves vs. Unspecified spinal nerve roots	1.24720308	1					
Distal upper extremities nerves vs. Unspecified spinal nerve roots	0.16639277	1					
Lumbar & sacral nerve roots vs. Unspecified spinal nerve roots	-0.19646375	1					
Lumbosacral plexus vs. Unspecified spinal nerve roots	1.36419144	1					
Thoracic nerve roots vs. Unspecified spinal nerve roots	-0.71268229	1					
Unspecified peripheral nerves vs. Unspecified spinal nerve roots	0.59997529	1					
Unspecified plexus vs. Unspecified spinal nerve roots	-0.08251123	1					

Time from Symptom Onset to Diagnosis							
Category & Types of Peripheral Nerves		N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Cranial nerves	Cranial nerves	26	3	9.014102564	18.82874852	0	40.65749705
	Brachial plexus	40	3	8.08875	13.67470651	0	30.34941302
Neural plexus	Lumbosacral plexus	42	3	9.266666667	20.28016807	0	43.56033613
	Unspecified plexus	0	N/A	N/A	N/A	N/A	N/A
Spinal nerves	Cervical nerve roots	13	5	11.92307692	16.57036279	0	38.14072559
	Thoracic nerve roots	8	5.5	29	42.02380278	0	89.54760556
	Lumbar & sacral nerve roots	17	3	10.70588235	23.05906738	0	49.11813475
	Unspecified spinal nerve roots	0	N/A	N/A	N/A	N/A	N/A
Peripheral nerves	Distal upper extremity nerves	15	3	9.893333333	24.02949576	0	51.05899153
	Distal lower extremity nerves	42	3	9.526984127	17.95227071	0	38.90454143
	Unspecified peripheral nerves	3	6	5.1	3.439476704	0	12.87895341
N/A = Not applicable							
Kruskal-Wallis chi-squared = 2.9153		df = 10	p value = 0.9396				
Pair	Zscore	Bonferroni adjusted p value					
Brachial plexus vs. Cervical nerve roots	-1.019157383	1					
Brachial plexus vs. Cranial nerves	-0.004629407	1					
Cervical nerve roots vs. Cranial nerves	0.954430849	1					
Brachial plexus vs. Distal lower extremity nerves	-0.001089024	1					
Cervical nerve roots vs. Distal lower extremity nerves	1.024403926	1					
Cranial nerves vs. Distal lower extremity nerves	0.003708285	1					
Brachial plexus vs. Distal upper extremities nerves	0.171515134	1					
Cervical nerve roots vs. Distal upper extremities nerves	0.995688993	1					
Cranial nerves vs. Distal upper extremities nerves	0.163754027	1					
Distal lower extremity nerves vs. Distal upper extremities nerves	0.173439711	1					
Brachial plexus vs. Lumbar & sacral nerve roots	-0.211638901	1					
Cervical nerve roots vs. Lumbar & sacral nerve roots	0.716798069	1					
Cranial nerves vs. Lumbar & sacral nerve roots	-0.192713802	1					
Distal lower extremity nerves vs. Lumbar & sacral nerve roots	-0.212320992	1					
Distal upper extremities nerves vs. Lumbar & sacral nerve roots	-0.319560746	1					
Brachial plexus vs. Lumbosacral plexus	0.162264543	1					
Cervical nerve roots vs. Lumbosacral plexus	1.138113199	1					
Cranial nerves vs. Lumbosacral plexus	0.14833142	1					
Distal lower extremity nerves vs. Lumbosacral plexus	0.165382881	1					
Distal upper extremities nerves vs. Lumbosacral plexus	-0.053458358	1					
Lumbar & sacral nerve roots vs. Lumbosacral plexus	0.337867317	1					
Brachial plexus vs. Thoracic nerve roots	-1.116484017	1					
Cervical nerve roots vs. Thoracic nerve roots	-0.238211558	1					
Cranial nerves vs. Thoracic nerve roots	-1.06663965	1					
Distal lower extremity nerves vs. Thoracic nerve roots	-1.120317359	1					
Distal upper extremities nerves vs. Thoracic nerve roots	-1.10631323	1					
Lumbar & sacral nerve roots vs. Thoracic nerve roots	-0.865635327	1					
Lumbosacral plexus vs. Thoracic nerve roots	-1.213872044	1					
Brachial plexus vs. Unspecified peripheral nerves	-0.348402808	1					
Cervical nerve roots vs. Unspecified peripheral nerves	0.18237389	1					
Cranial nerves vs. Unspecified peripheral nerves	-0.340125158	1					
Distal lower extremity nerves vs. Unspecified peripheral nerves	-0.348580401	1					
Distal upper extremities nerves vs. Unspecified peripheral nerves	-0.411864554	1					
Lumbar & sacral nerve roots vs. Unspecified peripheral nerves	-0.235191954	1					
Lumbosacral plexus vs. Unspecified peripheral nerves	-0.40896969	1					
Thoracic nerve roots vs. Unspecified peripheral nerves	0.330656	1					

Time from Symptom Onset to Death							
Category & Types of Peripheral Nerves		N	Median (months)	Mean (months)	Standard deviation	Lower bound	Upper bound
Cranial nerves	Cranial nerves	129	10	38.26	28.92546267	0	76.11547314
	Brachial plexus	103	9.996666667	22.69	33.91926048	0	90.52677339
Neural plexus	Lumbosacral plexus	122	12	26.24	40.34105844	0	106.9226907
	Unspecified plexus	27	10	10.88	1.518358688	7.844764105	13.91819886
Spinal nerves	Cervical nerve roots	43	5	14.08	23.64997249	0	61.38320079
	Thoracic nerve roots	30	5.5	38.31	29.34618567	0	77.00303801
	Lumbar & sacral nerve roots	62	7.78	38.25	22.92419097	0	64.09951097
	Unspecified spinal nerve roots	33	10	17.17	31.4554133	0	80.08234175
Peripheral nerves	Distal upper extremity nerves	31	5	13.28	24.09619209	0	61.46980353
	Distal lower extremity nerves	125	8	22.58	35.86550833	0	94.30984333
	Unspecified peripheral nerves	80	10	11.09	11.43378045	0	33.95793589
Kruskal-Wallis chi-squared = 33.352		df = 10	p value = 0.1584				
Pair		Z score	Bonferroni adjusted p value				
Distal upper extremities nerves vs. Unspecified plexus		-2.56858453	0.2808157				
Cervical nerve roots vs. Unspecified plexus		-2.51412714	0.3281504				
Brachial plexus vs. Distal upper extremities nerves		2.29690882	0.5946624				
Distal upper extremities nerves vs. Lumbosacral plexus		-2.29141518	0.6033338				
Brachial plexus vs. Cervical nerve roots		2.26766473	0.6421154				
Cervical nerve roots vs. Lumbosacral plexus		-2.26706929	0.6431148				
Brachial plexus vs. Cranial nerves		0.60944676	1				
Cervical nerve roots vs. Cranial nerves		-1.88079112	1				
Brachial plexus vs. Distal lower extremity nerves		0.78640823	1				
Cervical nerve roots vs. Distal lower extremity nerves		-1.73988761	1				
Cranial nerves vs. Distal lower extremity nerves		0.19217326	1				
Cervical nerve roots vs. Distal upper extremities nerves		0.24964284	1				
Cranial nerves vs. Distal upper extremities nerves		1.94979701	1				
Distal lower extremity nerves vs. Distal upper extremities nerves		1.82357256	1				
Brachial plexus vs. Lumbar & sacral nerve roots		0.30247953	1				
Cervical nerve roots vs. Lumbar & sacral nerve roots		-1.82962067	1				
Cranial nerves vs. Lumbar & sacral nerve roots		-0.20649498	1				
Distal lower extremity nerves vs. Lumbar & sacral nerve roots		-0.36070167	1				
Distal upper extremities nerves vs. Lumbar & sacral nerve roots		-1.93808839	1				
Brachial plexus vs. Lumbosacral plexus		0.0721824	1				
Cranial nerves vs. Lumbosacral plexus		-0.56119959	1				
Distal lower extremity nerves vs. Lumbosacral plexus		-0.74640169	1				
Lumbar & sacral nerve roots vs. Lumbosacral plexus		-0.24980988	1				
Brachial plexus vs. Thoracic nerve roots		1.28906142	1				
Cervical nerve roots vs. Thoracic nerve roots		-0.60653007	1				
Cranial nerves vs. Thoracic nerve roots		0.92209766	1				
Distal lower extremity nerves vs. Thoracic nerve roots		0.80069236	1				
Distal upper extremities nerves vs. Thoracic nerve roots		-0.79303814	1				
Lumbar & sacral nerve roots vs. Thoracic nerve roots		0.98387546	1				
Lumbosacral plexus vs. Thoracic nerve roots		1.26492143	1				
Brachial plexus vs. Unspecified peripheral nerves		0.55936367	1				
Cervical nerve roots vs. Unspecified peripheral nerves		-1.73651238	1				
Cranial nerves vs. Unspecified peripheral nerves		0.01987302	1				
Distal lower extremity nerves vs. Unspecified peripheral nerves		-0.14870224	1				
Distal upper extremities nerves vs. Unspecified peripheral nerves		-1.8301105	1				
Lumbar & sacral nerve roots vs. Unspecified peripheral nerves		0.20531038	1				
Lumbosacral plexus vs. Unspecified peripheral nerves		0.51229717	1				
Thoracic nerve roots vs. Unspecified peripheral nerves		-0.85982011	1				
Brachial plexus vs. Unspecified plexus		-0.95099977	1				
Cranial nerves vs. Unspecified plexus		-1.3520748	1				
Distal lower extremity nerves vs. Unspecified plexus		-1.46199754	1				
Lumbar & sacral nerve roots vs. Unspecified plexus		-1.10259776	1				
Lumbosacral plexus vs. Unspecified plexus		-1.01217783	1				
Thoracic nerve roots vs. Unspecified plexus		-1.78324837	1				
Unspecified peripheral nerves vs. Unspecified plexus		-1.29835228	1				
Brachial plexus vs. Unspecified spinal nerve roots		-0.12989041	1				
Cervical nerve roots vs. Unspecified spinal nerve roots		-1.89131243	1				
Cranial nerves vs. Unspecified spinal nerve roots		-0.54600795	1				
Distal lower extremity nerves vs. Unspecified spinal nerve roots		-0.66747467	1				
Distal upper extremities nerves vs. Unspecified spinal nerve roots		-1.98511661	1				
Lumbar & sacral nerve roots vs. Unspecified spinal nerve roots		-0.34621549	1				
Lumbosacral plexus vs. Unspecified spinal nerve roots		-0.38164253	1				
Thoracic nerve roots vs. Unspecified spinal nerve roots		-1.16314599	1				
Unspecified peripheral nerves vs. Unspecified spinal nerve roots		-0.52850393	1				
Unspecified plexus vs. Unspecified spinal nerve roots		0.69222283	1				